

## ECFS NEWSLETTER - Issue 59 - January 2019

01. Letter from the President
02. Upcoming Events
03. Deadlines
04. ECFS Award - Call for nominations
05. Gerd Döring Award - Call for nominations
06. ECFS Board Elections - Call for nominations
07. Editor-in-Chief of the Journal of Cystic Fibrosis
08. ECFS Education - New feature on the platform!
09. Welcome to Emily!
10. ECFS Meetings - CTN, Patient Registry, Standards of Care
11. 16<sup>th</sup> European Basic Science Conference
12. ECFS REAP Meeting 29-30 March 2019
13. 42nd European CF Conference - Liverpool
14. New course! Acceptance & Commitment Therapy for CF care
15. New course! Nutrition advanced course - scrutinizing the future for nutrition in cystic fibrosis
16. Physiotherapy short course - Exercise testing in CF - who, when and why
17. An introductory course in Cognitive Behavioural Therapy and Interpersonal Therapy
18. Current References in CF

European Cystic Fibrosis Society  
Kastanieparken 7  
7470 Karup, Denmark  
Tel: +45 86 676260  
Fax: +45 86 676290  
[info@ecfs.eu](mailto:info@ecfs.eu)  
[www.ecfs.eu](http://www.ecfs.eu)

### 01. Letter from the President

Dear Friends,

I hope you had a good start of the year. I wish you and your family all the best for 2019!

2018 was another busy year for the European Cystic Fibrosis Society, with not only the Basic Science Conference in Greece and the Annual conference in Belgrade, but a number of special projects and Working Group meetings were held and some selected updates are given below. I would just like to highlight that, thanks to Daniel Peckham who leads the Education project with the help of Helen Chadwick as coordinator, the ECFS Education platform was launched last December. Please follow the instructions on the education homepage (<https://www.ecfs.eu/education>) and discover a selection of courses and webcasts from the Seville and Belgrade ECFS conferences, and a library of educational resources. Each month, you will also find a selection of courses on a specific topic: "new therapies" were the topic of January, and this month, you will learn everything about "lung microbiology". Read more about it below!



There will be ECFS Board elections in 2019 as Margarida Amaral and Isabelle Sermet-Gaudelus will finish their terms in June. I would like to encourage you all to consider your own nomination or to nominate an ECFS member you believe would benefit the ECFS community by being actively engaged in the Board. Please consider how important these elections are for the future of the Society. Further information about the elections is included later in the Newsletter.

Planning for the 2019 Conference is well underway with all necessary information available on the website. I would like to thank all those who have submitted abstracts and all the speakers who have accepted to contribute to the conference. For the second year, there is a special discounted rate for attendees from lower income countries in an effort to encourage participation of healthcare professionals from all countries. We have excellent programmes and courses planned and we look forward to your participation.

We have a lot to do over the coming months and I hope you will join us for some of these activities.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in cystic fibrosis contained in this Newsletter

Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,

Isabelle Fajac, ECFS President

## 02. Upcoming Events

- ECFS Diagnostic Network Working Group Meeting - 14-16 February 2019, Tunis, Tunisia
- 13th European Young Investigators Meeting - 27 February - 01 March 2019, Paris, France
- 16th ECFS Basic Science Conference - 27-30 March 2019, Dubrovnik, Croatia
- ECFS REAP Meeting - 29-30 March 2019, Postdam, Germany
- ECFS Board Elections - Polls will open 15 May 2019
- ECFS Board Meeting - 04 June 2019, Liverpool, United Kingdom
- 42<sup>nd</sup> European CF Conference - 05-08 June 2019, Liverpool, United Kingdom



5 – 8 JUNE 2019  
LIVERPOOL, UNITED KINGDOM



Not registered yet? Please find all details [here](#)

## 03. Deadlines

- |  |                  |
|--|------------------|
| - Nomination ECFS Award                                  | 22 February 2019 |
| - Nomination Gerd Döring Award                           | 22 February 2019 |
| - Nomination ECFS Board Election                         | 15 March 2019    |
| - Application Journal of Cystic Fibrosis Editor-in-Chief | 31 March 2019    |

## 04. ECFS Award - Call for nominations

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of cystic fibrosis or to the treatment or care of patients with cystic fibrosis. The winner of the award will be invited to present a lecture at the Opening Plenary on 5 June 2019 of the annual conference in Liverpool.

You are cordially invited to nominate a candidate for this award. The deadline for proposals is **22 February, 2019**. Please mail your proposal, accompanied by a detailed motivation and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois ([christine.dubois@ecfs.eu](mailto:christine.dubois@ecfs.eu)).

## 05. Gerd Döring Award - Call for nominations

The Gerd Döring Award is an initiative of the European Cystic Fibrosis Society and is given annually to honour an exceptional young European scientist in their early career. The Award, a monetary donation of 5,000 euro to support research, will be presented at the Opening Plenary of the annual ECFS conference in Liverpool.

The award will be judged primarily on a paper published in the previous 3 calendar years (2016-2018) which has made a significant impact on the understanding or treatment of Cystic Fibrosis. Personal statements and CVs will make a 20% contribution to the scoring.

The award is open to PhD students and post-doctoral researchers with up to a maximum of four years' academic research experience following the completion of their PhD, or be of equivalent professional standing at the date of publication of the paper.

We encourage mentors, supervisors and co-workers of today's most exceptional early career European scientists to send in nominations for this competition. The deadline for proposals is **22 February, 2019**. Please mail your proposal, accompanied by a detailed personal statement, a PDF of the nominated paper and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu)

## 06. ECFS Board Elections - Call for nominations



The ECFS cordially invites nominations for 2 Board positions.

Margarida Amaral is ending her second term and Isabelle Sermet-Gaudelus will finish her first term on the Board in 2019.

Job Descriptions and person specifics are available for Board members. [Board Member's Job Description](#).

Nominations should be sent to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu) by **15 March 2019** together with a personal statement, confirmation that the candidate has agreed to the nomination, and a curriculum vitae. All nominated candidates must be current members of the ECFS. Information about the nominated candidates will be sent to the membership in April for an online vote prior to the Annual General Meeting in June where the results will be announced.

## 07. Editor-in-Chief of the Journal of Cystic Fibrosis (JCF)

The European Cystic Fibrosis Society (ECFS) is looking to appoint the next Editor-in-Chief of the Journal of Cystic Fibrosis (JCF).

The current Editor-in-Chief, Scott Bell, will complete his mandate on June 30, 2020. It is anticipated that the next Editor-in-Chief will work very closely with the incumbent from July 2019, assuming full responsibility in July 2020. The ECFS is seeking candidates with the following qualities for this challenging position: previous international editorial experience, organisational ability, leadership skills, prestige in the field, willingness to devote time to the JCF and ECFS, and the ability to communicate clearly.

A more detailed job description for the role of the JCF Editor-in-Chief can be found [here](#).

To apply, please send a CV and a covering letter of suitability for the post to the ECFS office info@ecfs.eu by the deadline 31 March 2019. Interviews of selected candidates will be held in June during the 42nd European Cystic Fibrosis conference.

## 08. ECFS Education - New feature on the platform!



The ECFS Education launched a new feature on the Education Platform. Each month we will be posting a 'Highlight of the month' which will include relevant talks and material on a particular topic.

In case you missed it, the topic for January 2019 was 'New Therapies', and brought together talks from the ECFS conferences in Belgrade (2018) and Seville (2017), and a presentation from 'The Treatment of Adults with CF' course. They are still available on the platform!

The topic for February 2019 is 'lung microbiology' and brings together symposiums from the ECFS conferences in Belgrade (2018) and Seville (2017), two talks from 'The Treatment of Adults with CF' course, and a presentation (available in English and Spanish) from 'The Essential Toolkit' course.

Join us on the Education Platform [here](#)

## 09. Welcome to Emily!

A few weeks ago, Emily Bateman joined the ECFS Executive team as Administrative and Events coordinator.

Emily is a trained speech and language therapist. When working at the NHS, she was involved in the design, delivery and organisation of formal training packages for staff working within schools and has some experience with event organisation.

She will mainly focus on the membership and the organisation of the conferences. Emily is an enthusiastic person and we are happy that she will strengthen the team.



## 10. ECFS Meetings - CTN, Patient Registry, Standards of Care



*ECFS Registry Steering Committee*

The ECFS Clinical Trials Network, the ECFS Patient Registry Steering Committees met on 24-25 January in Brussels for their annual winter meetings. The Standards of Care Group also met in



Brussels. This was an excellent opportunity to meet across ECFS projects, discuss common subjects and find new and even better opportunities for cooperation.



*ECFS - CTN Steering Committee*

## 11. 16th European Basic Science Conference

The 2019 ECFS Basic Science Conference will take place in Dubrovnik, Croatia, from 27 to 30 March 2019.

We are delighted that Prof. Isabelle Callebaut (FR) has accepted to be the conference chairperson, supported by Prof. Carlos Farinha (PT) and Dr. Martin Mense (US).

We have an exciting programme this year again and we look forward to fruitful discussions of data and ideas in an informal and interactive environment. Learn more [here](#).

## 12. ECFS REAP Meeting 29-30 March 2019

We are happy to announce the ECFS regional educational activities platform (ECFS-REAP) meeting, which will be held 29 and 30 March in Postdam, Germany. This meeting will be of special interest to physicians and scientists who are/or want to be involved in gastrointestinal or/and otorhinological issues in cystic fibrosis. The programme details can be found [here](#). Unfortunately, there is limited seating and an application is to be sent to the organisers before registration. The application form can be found [here](#) and is to be sent to the coordinator of the meeting, Katja Erler, [katja.erler@med.uni-jena.de](mailto:katja.erler@med.uni-jena.de)

## 13. 42<sup>nd</sup> European CF Conference - Liverpool, United Kingdom



The Annual Conference is fast approaching. We had a record number of abstract submissions (close to 700!) and we are sure we will have a record attendance in Liverpool. To ease the access for all, we have a limited number of single day registration available and hope it will answer the flexibility needs of the delegates. We have also introduced a Team ticket, allowing 3 allied health professionals from the same team to share a registration, more information on the Team ticket [here](#). Last year we introduced a reduced registration rate for participants working in countries classified as low-income economies, lower-middle-income economies and upper-middle-income economies by the World Bank. We hope this opportunity will encourage many more healthcare professionals to attend the conference. All information concerning the registration to the conference can be found [here](#). And do not forget to have a look at the scientific programme [here](#).

## 14. New course! Acceptance and Commitment Therapy for CF care

Tuesday 4 June 2019 - All day

Acceptance & Commitment Therapy (ACT) is an evidence-based “3rd wave” therapy that aims to help people live fulfilling lives even in the presence of difficult experiences, and the powerful thoughts and feelings that they will inevitably bring. This short course will introduce the use of ACT in supporting people with serious physical health problems, with specific reference to cystic fibrosis. Through teaching, experiential exercises and role-play, participants will learn how people can become more Aware, Open and Engaged, and use these skills to live more fulfilling lives in the presence of serious physical difficulties. Although the course assumes no prior knowledge of the ACT model, it is only open to psychosocial professionals active in CF care, and who have some experience/knowledge of psychological therapy and active listening/counselling.

[Registration information](#)

## 15. New course! Nutrition advanced course - scrutinizing the future for nutrition in cystic fibrosis

(Limited Seating) Tuesday 4 June - Half Day

This nutrition advanced course will be looking at the latest and future developments in nutrition aspects in cystic fibrosis. Emerging topics and the data that underpin them will be critically presented and explored, leaving room for interaction and discussions. Participants will be presented with an overview of possible challenges and changes facing nutritional management in the future. This course is meant for experienced health care nutrition providers including advanced dietitians, GI leads and all CF team members

[Registration information](#)

## 16. Physiotherapy short course - Exercise testing in CF - who, when and why

Tuesday 4 June & Wednesday 5 June 2019 - One and a half days

The course is suitable for those new to exercise testing, by providing attendees with an understanding of exercise physiology as well as an overview of available tests, before focusing on the utility of cardiopulmonary exercise testing (CPET) in CF. The course is also applicable to those with experience of exercise testing, and will help build on existing knowledge with sessions dedicated to interpreting and reporting CPET data; as well as how CPET results can be translated into individualised exercise training plans for people with CF. The course will include both theory and practical exercise testing sessions, whilst small group sessions allow lots of opportunity for discussion between participants and course tutors.

[Registration information](#)



## 17. An introductory course in Cognitive Behavioural Therapy and Interpersonal Therapy

Wednesday 05 June 2019 - All day

The course is intended for any member of the CF multidisciplinary team who wants to be introduced to, or updated about, Cognitive Behavioural Therapy (CBT) and Interpersonal Therapy (IPT) with the aim of improving mental health care for patients with cystic fibrosis and their families. This one-day course consists of a basic introduction in CBT and IPT. The course will highlight the principles of assessment and a variety of intervention techniques. CBT and IPT have been applied in medical settings for decades and the course will include examples of CBT and IPT approaches in CF

[Registration information](#)

## 18. Current references in CF

Please scroll to next page for full list



## CF Reference List

(compiled between October 2018 – January 2019)

### Adults & Adolescents

**Connett GJ., Nagra A.**

Ready, Steady, Go - Achieving successful transition in cystic fibrosis  
*Paediatric Respiratory Reviews* 2018; 27: 13 - 15

**Cordeiro SM., de Jesus MCP., Tavares RE., de Oliveira DM., Merighi MAB.**

Experience of adults with cystic fibrosis: a perspective based on social phenomenology  
*Revista Brasileira de Enfermagem* 2018; 71: 2891 - 2898

**Coyne I., Malone H., Chubb E., While AE.**

Transition from paediatric to adult healthcare for young people with cystic fibrosis: Parents' information needs  
*Journal of Child Health Care* 2018; 22: 646 - 657

**Giordani B., Quattrucci S., Amato A., Salvatore M., Padoan R.**

A case-control study on pregnancy in Italian Cystic Fibrosis women. Data from the Italian Registry  
*Respiratory Medicine* 2018; 145: 200 - 205

**Hong G., Lechtzin N., Hadjiladis D., Kawut SM.**

Inhaled antibiotic use is associated with *Scedosporium/Lomentospora* species isolation in cystic fibrosis  
*Pediatric Pulmonology* 2019; 54: 133 - 140

**King CS., Brown AW., Aryal S., Ahmad K., Donaldson S.**

Critical Care of the Adult Patient With Cystic Fibrosis  
*Chest* 2019; 155: 202 - 214

**Li L., Somerset S.**

Associations between Flavonoid Intakes and Gut Microbiota in a Group of Adults with Cystic Fibrosis  
*Nutrients* 2018; 10: 9:1264

**Regard L., Lafaeste H., Martin C., Chassagnon G., Burgel PR.**

Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis  
*Revue de Pneumologie Clinique* 2018; 74: 279 - 291

**Schmid-Mohler G., Caress AL., Spirig R., Benden C., Yorke J.**

"Thrust out of normality"-How adults living with cystic fibrosis experience pulmonary exacerbations: A qualitative study  
*Journal of Clinical Nursing* 2019; 28: 190 - 200

**Simon SL., Vigers T., Campbell K., Pyle L., Branscomb R., Nadeau KJ., Chan CL.**

Reduced insulin sensitivity is correlated with impaired sleep in adolescents with cystic fibrosis  
*Pediatric Diabetes* 2018; 19: 1183 - 1190

**Skov M., Teilmann G., Damgaard IN., Nielsen KG., Hertz PG., Holgersen MG., Presfeldt M., Dalager AMS., Brask M., Boisen KA.**

Initiating transitional care for adolescents with cystic fibrosis at the age of 12 is both feasible and promising  
*Acta Paediatrica* 2018; 107: 1977 - 1982

**Staab D., Schwarz C.**

Cystic fibrosis. A new disease pattern in adult medicine  
*Internist* 2018; 59: 1138 - 1145

**Tomaszek L., Cepuch G., Pawlik L.**

Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis  
*Biomedical Papers-olomouc* 2018; 162: 212 - 218

### Animal Model

**Bederman I., DiScenna A., Henderson L., Perez A., Klavanian J., Kovtun D., Collins O., Dunn J., Erokwu B., Flask CA., Drumm ML.**

Small adipose stores in cystic fibrosis mice are characterized by reduced cell volume, not cell number  
*American Journal of Physiology-gastrointestinal and Liver Physiology* 2018; 315: G943 - G953

**Bederman IR., Pora G., O'Reilly M., Poleman J., Spoonhower K., Puchowicz M., Perez A., Erokwu BO., Rodriguez-Palacios A., Flask CA., Drumm ML.**

Absence of leptin signaling allows fat accretion in cystic fibrosis mice  
*American Journal of Physiology-Gastrointestinal and Liver Physiology* 2018; 315: G685 - G698

**Cooney AL., Singh BK., Loza LM., Thornell IM., Hippee CE., Powers LS., Ostedgaard LS., Meyerholz DK., Wohlford-Lenane C., Stoltz DA., McCray PB., Sinn PL.**

Widespread airway distribution and short-term phenotypic correction of cystic fibrosis pigs following aerosol delivery of piggyBac/adenovirus  
*Nucleic Acids Research* 2018; 46: 9591 - 9600

**Debray D., El Mourabit H., Merabtene F., Brot L., Ulveling D., Chretien Y., Rainteau D., Moszer I., Wendum D., Soko H., Housset C.**

Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice  
*Hepatology Communications* 2018; 2: 1533 - 1549

**Fan ZQ., Perisse IV., Cotton CU., Regouski M., Meng QG., Domb C., Van Wettene AJ., Wang ZD., Harris A., White KL., Polejaeva IA.**

A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene  
*JCI Insight* 2018; 3: 19:e123529

**Keitsch S., Riethmuller J., Soddemann M., Sehl C., Wilker B., Edwards MJ., Caldwell CC., Fraunholz M., Gulbins E., Becker KA.**

Pulmonary infection of cystic fibrosis mice with *Staphylococcus aureus* requires expression of alpha-toxin  
*Biological Chemistry* 2018; 399: 1203 - 1213

**Liu Y., Feng L., Wang H., Wang YJ., Chan HC., Jiang XH., Fu WM., Li G., Zhang JF.**

Identification of an Anti-Inflammation Protein, Annexin A1, in Tendon Derived Stem Cells (TDSCs) of Cystic Fibrosis Mice: A Comparative Proteomic Analysis  
*Proteomics Clinical Applications* 2018; 12: 6:1700162

**Lord R., Fairbourn N., Mylavaram C., Dbeis A., Bowman T., Chandrashekar A., Banayat T., Hodges CA., Al-Nakkash L.**

Consuming Genistein Improves Survival Rates in the Absence of Laxative in Delta F508-CF Female Mice  
*Nutrients* 2018; 10: 10:1418

**McHugh DR., Cotton CU., Mass FJ., Vitko M., Valerio DM., Kelley TJ., Hao SY., Jafri A., Drumm ML., Boron WF., Stern RC., McBennett K., Hodges CA.**

Linacotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3  
*American Journal of Physiology-gastrointestinal and Liver Physiology* 2018; 315: G868 - G878

**Semaniakou A., Croll RP., Chappe V.**

Animal Models in the Pathophysiology of Cystic Fibrosis  
*Frontiers in Pharmacology* 2019; 9: ArNo: 1475

**Xie YL., Ostedgaard L., Abou Alaiwa MH., Lu L., Fischer AJ., Stoltz DA.**

Mucociliary Transport in Healthy and Cystic Fibrosis Pig Airways  
*Annals of the American Thoracic Society* 2018; 15:

### Antimicrobials

**Abdoulrasouli A., Scourfield A., Rhodes J., Shah A., Elborn JS., Fisher MC., Schelenz S., Armstrong-James D.**

High prevalence of triazole resistance in clinical *Aspergillus fumigatus* isolates in a specialist cardiothoracic centre  
*International Journal of Antimicrobial Agents* 2018; 52: 637 - 642

**Agarwal R., Johnson CT., Imhoff BR., Donlan RM., McCarty NA., Garcia AJ.**

Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections  
*Nature Biomedical Engineering* 2018; 2: 841 - 849

- Arooj P., Plant R., Doddakula K., Plant BJ.**  
Inhaler screw-up: A real world cystic fibrosis (CF) case  
*Pediatric Pulmonology* 2019; 54: E1 - E3
- Beaudoin T., Stone TA., Glibowicka M., Adams C., Yau Y., Ahmadi S., Bear CE., Grasmann H., Waters V., Deber CM.**  
Activity of a novel antimicrobial peptide against *Pseudomonas aeruginosa* biofilms  
*Scientific Reports* 2018; 8: ArNo: 14728
- Dentice R., Elkins M.**  
Timing of dornase alfa inhalation for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 11:CD007923
- Diez-Aguilar M., Ekkelenkamp M., Morosini ML., Merino I., Caballero JD., Jones M., van Westreenen M., Tunney MM., Canton R., Fluit AC.**  
Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients  
*International Journal of Antimicrobial Agents* 2019; 53: 84 - 88
- Ernst J., Klinger-Strobel M., Arnold K., Thamm J., Hartung A., Pletz MW., Makarewicz O., Fischer D.**  
Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions  
*European Journal of Pharmaceutics and Biopharmaceutics* 2018; 131: 120 - 129
- Farfoue E., Trochu E., Devin C., Martin EC., Limousin L., Roux A., Picard C., Jolly E., Vasse M., Lesprit P.**  
Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients  
*Transplant Infectious Disease* 2018; 20: 5:e12955
- Fong J., Mortensen KT., Norskov A., Qvortrup K., Yang L., Tan CH., Nielsen TE., Givskov M.**  
Itaconimides as Novel Quorum Sensing Inhibitors of *Pseudomonas aeruginosa*  
*Frontiers in Cellular and Infection Microbiology* 2019; 8: ArNo: 443
- Gleser MA., Zettner EM.**  
Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients  
*International Journal of Audiology* 2018; 57: 917 - 924
- Hoppe JE., Wagner BD., Accurso FJ., Zemanick ET., Sagel SD.**  
Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 760 - 768
- Hussein M., Han ML., Zhu Y., Schneider-Futschik EK., Hu XH., Zhou QT., Lin YW., Anderson D., Creek DJ., Hoyer D., Li J., Velkov T.**  
Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR *Pseudomonas aeruginosa*  
*Computational and Structural Biotechnology Journal* 2018; 16: 587 - 599
- Illamola SM., Huynh HQ., Liu XX., Bhakta ZN., Sherwin CM., Liou TG., Carveth H., Young DC.**  
Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis  
*Antimicrobial Agents and Chemotherapy* 2018; 62: 10:e00877-18
- Jain K., Wainwright C., Smyth AR.**  
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 9:CD009530
- Kidd TJ., Canton R., Ekkelenkamp M., Johansen HK., Gilligan P., LiPuma JJ., Bell SC., Elborn JS., Flume PA., VanDevanter DR., Waters VJ.**  
Defining antimicrobial resistance in cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 696 - 704
- Kirkwood ZL., Millar BC., Downey DG., Moore JE.**  
Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus  
*International Journal of Mycobacteriology* 2018; 7: 358 - 360
- Lhuissier M., Person C., Urban T., Drouet M.**  
Antibiotics allergy in cystic fibrosis: A retrospective cohort of adult patients followed at the resource and skills centre for cystic fibrosis in Angers with a literature review  
*Revue Francaise D Allergologie* 2018; 58: 513 - 524
- Lin Q., Deslouches B., Montelaro RC., Di YP.**  
Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37  
*International Journal of Antimicrobial Agents* 2018; 52: 667 - 672
- Lin Y., Chang RYK., Britton WJ., Morales S., Kutter E., Chan HK.**  
Synergy of nebulized phage PEV20 and ciprofloxacin combination against *Pseudomonas aeruginosa*  
*International Journal of Pharmaceutics* 2018; 551: 158 - 165
- Mayer-Hamblett N., Retsch-Bogart G., Kloster M., Accurso F., Rosenfeld M., Albers G., Black P., Brown P., Cairns A., Davis SD., Graff GR., Kerby GS., Orenstein D., Buckingham R., Ramsey BW.**  
Azithromycin for Early *Pseudomonas* Infection in Cystic Fibrosis The OPTIMIZE Randomized Trial  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1177 - 1187
- Moore JE., Koulianos G., Hardy M., Misawa N., Millar BC.**  
Antimycobacterial Activity of Veterinary Antibiotics (Apramycin and Framycetin) against *Mycobacterium abscessus*: Implication for Patients with Cystic Fibrosis  
*International Journal of Mycobacteriology* 2018; 7: 265 - 267
- Moore RE., Millar BC., Panickar JR., Moore JE.**  
Interaction of South Asian Spices with Conventional Antibiotics: Implications for Antimicrobial Resistance for *Mycobacterium abscessus* and Cystic Fibrosis  
*International Journal of Mycobacteriology* 2018; 7: 257 - 260
- Muller L., Murgia X., Siebenburger L., Borger C., Schwarzkopf K., Sewald K., Haussler S., Braun A., Lehr CM., Hittinger M., Wronski S.**  
Human airway mucus alters susceptibility of *Pseudomonas aeruginosa* biofilms to tobramycin, but not colistin  
*Journal of Antimicrobial Chemotherapy* 2018; 73: 2762 - 2769
- Munoz AJ., Alasino RV., Garro AG., Heredia V., Garcia NH., Cremonesi DC., Beltramo DM.**  
High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens  
*Pharmaceuticals* 2018; 11: 2:UNSP 47
- Naguib MM., Valvano MA.**  
Vitamin E Increases Antimicrobial Sensitivity by Inhibiting Bacterial Lipocalin Antibiotic Binding  
*Mosphere* 2018; 3: 6:e00564-18
- Philly JV., Griffith DE.**  
Medical Management of Pulmonary Nontuberculous Mycobacterial Disease  
*Thoracic Surgery Clinics* 2019; 29: 65 -
- Rees VE., Yadav R., Rogers KE., Bulitta JB., Wirth V., Oliver A., Boyce JD., Peleg AY., Nation RL., Landersdorfer CB.**  
Meropenem Combined with Ciprofloxacin Combats Hypermutable *Pseudomonas aeruginosa* from Respiratory Infections of Cystic Fibrosis Patients  
*Antimicrobial Agents and Chemotherapy* 2018; 62: 11:e01150-18
- Retsch-Bogart G., Mayer-Hamblett N., Ramsey BW.**  
Azithromycin for Early *Pseudomonas* Infection in Cystic Fibrosis: Do the Benefits Outweigh the Harms? Reply  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1349 - 1350
- Saad EY., Leung WM., Smith MP., Salgado J., Hassan I., Brown NE.**  
Comparison of home and hospital intravenous antibiotic therapy for clinical outcome in patients with a pulmonary exacerbation of cystic fibrosis. Do they always need to be admitted?  
*Canadian Journal of Respiratory Critical Care and Sleep Medicine* 2018; 2: 133 - 137

**Shanthikumar S., Robertson C., Ranganathan S.**

Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: Do the Benefits Outweigh the Harms?

*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1348 - 1349

**Smith S., Rowbotham NJ., Charbek E.**

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis

*Cochrane Database of Systematic Reviews* 2018; : 10:CD008319

**Spero MA., Newman DK.**

Chlorate Specifically Targets Oxidant-Starved, Antibiotic-Tolerant Populations of Pseudomonas aeruginosa Biofilms

*mBio* 2018; 9: 5:e01400-18

**Tunney MM., Payne JE., McGrath SJ., Einarsson GG., Ingram RJ., Gilpin DF., Juarez-Perez V., Elborn JS.**

Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputum

*Journal of Antimicrobial Chemotherapy* 2018; 73: 3391 - 3397

**Wright MFA., Bush A., Carr SB.**

Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis

*Paediatric Respiratory Reviews* 2018; 27: 9 - 12

**Ye TT., Sun SP., Sugianto TD., Tang P., Parumasivam T., Chang YK., Astudillo A., Wang SJ., Chan HK.**

Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms

*International Journal of Pharmaceutics* 2018; 552: 130 - 138

**Zettner EM., Gleser MA.**

Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment

*Otolaryngology-Head and Neck Surgery* 2018; 159: 887 - 894

**Zhou JW., Hou B., Liu GY., Jiang H., Sun B., Wang ZN., Shi RF., Xu Y., Wang R., Jia AQ.**

Attenuation of Pseudomonas aeruginosa biofilm by hordenine: a combinatorial study with aminoglycoside antibiotics

*Applied Microbiology and Biotechnology* 2018; 102: 9745 - 9758

## Cardiology

**Bakhshayeshkaram M., Aghahosseini F., Vaezi F., Kahkooei S., Salehi Y., Hassanzad M., Jamaati HR., Velayati AA.**

CT-measured pulmonary artery diameter as an independent predictor of pulmonary hypertension in cystic fibrosis

*Polish Journal of Radiology* 2018; 83:

**Causar AJ., Shute JK., Cummings MH., Shepherd AI., Bright V., Connett G., Allenby MI., Carroll MP., Daniels T., Saynor ZL.**

Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of  $\dot{V}_{O_2\max}$  in people with cystic fibrosis: a retrospective analysis

*Journal of Applied Physiology* 2018; 125: 1277 - 1283

**Eising JB., van der Ent CK., Teske AJ., Vanderschuren MM., Uiterwaal CSPM., Meijboom FJ.**

Young patients with cystic fibrosis demonstrate subtle alterations of the cardiovascular system

*Journal of Cystic Fibrosis* 2018; 17: 643 - 649

**Hussain N., Hussain F., Malik A., Rizvi M., Patel P., Chittivelu S.**

A devastating cardiovascular event in an adult cystic fibrosis patient: An unforeseen outcome of increasing life expectancy

*Respiratory Medicine Case Reports* 2018; 25: 233 - 234

## Cell Biology

**Awatade NT., Wong SL., Hewson CK., Fawcett LK., Kicic A., Jaffe A., Waters SA.**

Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine

*Frontiers in Pharmacology* 2018; 9: ArNo: 1429

**Balazs A., Mall MA.**

Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis

*Frontiers in Pharmacology* 2018; 9: ArNo: 1112

**Bebok Z., Fu LW.**

Stressors and Stress Responses in Cystic Fibrosis

*Endoplasmic Reticulum Stress in Diseases* 2018; 5: 11 - 29

**Bouvet GF., Voisin G., Cyr Y., Bascunana V., Masse C., Berthiaume Y.**

DNA Methylation Regulates RGS2-induced S100A12 Expression in Airway Epithelial Cells

*American Journal of Respiratory Cell and Molecular Biology* 2018;

59: 601 - 613

**Canato S., Santos JD., Carvalho AS., Aloria K., Amaral MD., Matthiesen R., Falcao AO., Farinha CM.**

Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation

*Cellular and Molecular Life Sciences* 2018; 75: 4495 - 4509

**Castellani S., Di Gioia S., di Toma L., Conese M.**

Human Cellular Models for the Investigation of Lung Inflammation and Mucus Production in Cystic Fibrosis

*Analytical Cellular Pathology* 2018; : ArNo: 3839803

**Chen QW., Pandi SPS., Kerrigan L., McElvaney NG., Greene CM., Elborn JS., Taggart CC., Weldon S.**

Cystic fibrosis epithelial cells are primed for apoptosis as a result of increased Fas (CD95)

*Journal of Cystic Fibrosis* 2018; 17: 616 - 623

**Conese M., Beccia E., Carbone A., Castellani S., Di Gioia S., Corti F., Angiolillo A., Colombo C.**

The role of stem cells in cystic fibrosis disease modeling and drug discovery

*Expert Opinion On Orphan Drugs* 2018; 6: 707 - 717

**Delpiano L., Thomas JJ., Yates AR., Rice SJ., Gray MA., Saint-Criq V.**

Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells

*Frontiers in Pharmacology* 2018; 9: ArNo: 1462

**Gianotti A., Delpiano L., Caci E.**

In vitro Methods for the Development and Analysis of Human Primary Airway Epithelia

*Frontiers in Pharmacology* 2018; 9: ArNo: 1176

**Imberti R., Garavaglia ML., Verduci I., Cannavale G., Balduzzi G., Papetti S., Mazzanti M.**

Antiestrogen- and tamoxifen-induced effects on calcium-activated chloride currents in epithelial cells carrying the Delta F508-CFTR point mutation

*Respiratory Research* 2018; 19: ArNo: 198

**Li H., Ma NX., Wang J., Wang Y., Yuan C., Wu J., Luo MH., Yang JL., Chen J., Shi J., Liu XM.**

Nicotine Induces Progressive Properties of Lung Adenocarcinoma A549 Cells by Inhibiting Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Expression and Plasma Membrane Localization

*Technology in Cancer Research & Treatment* 2018; 17:

**Lopes-Pacheco M., Kitoko JZ., Morales MM., Petrs-Silva H., Rocco PRM.**

Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells

*Experimental Cell Research* 2018; 372: 99 - 107

**Perra L., Balloy V., Foussigniere T., Moissenet D., Petat H., Mungrue IN., Touqui L., Corvol H., Chignard M., Guillot L.**

CHAC1 Is Differentially Expressed in Normal and Cystic Fibrosis Bronchial Epithelial Cells and Regulates the Inflammatory Response Induced by Pseudomonas aeruginosa

*Frontiers in Immunology* 2018; 9: ArNo: 2823

**Pesce E., Sondo E., Ferrera L., Tomati V., Caci E., Scudieri P., Musante I., Renda M., Baatallah N., Servel N., Hinzpeter A., di Bernardo D., Pedemonte N., Galletta LJV.**

The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism

*Frontiers in Pharmacology* 2018; 9: ArNo: 1464

**Ringholz FC., Higgins G., Hatton A., Sassi A., Moukachar A., Fustero-Torre C., Hollenhorst M., Sermet-Gaudelus I., Harvey BJ., McNally P., Urbach V.**

Resolvin D1 regulates epithelial ion transport and inflammation in cystic fibrosis airways

*Journal of Cystic Fibrosis* 2018; 17: 607 - 615

**Scudieri P., Musante I., Caci E., Venturini A., Morelli P., Walter C., Tosi D., Palleschi A., Martin-Vasallo P., Sermet-Gaudelus I., Planelles G., Crambert G., Galiotta LJV.**

Increased expression of ATP12A proton pump in cystic fibrosis airways

*JCI Insight* 2018; 3: 20:e123616

**Shei RJ., Peabody JE., Kaza N., Rowe SM.**

The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis

*Current Opinion in Pharmacology* 2018; 43: 152 - 165

**Tagalakis AD., Munye MM., Ivanova R., Chen HP., Smith CM., Aldossary AM., Rosa LZ., Moulding D., Barnes JL., Kafetzis KN., Jones SA., Baines DL., Moss GWJ., O'Callaghan C., McNulty RJ., Hart SL.**

Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung

*Thorax* 2018; 73: 847 - 856

**Wang C., Aleksandrov AA., Yang ZR., Forouhar F., Proctor EA., Kota P., An JL., Kaplan A., Khazanov N., Boel G., Stockwell BR., Senderowitz H., Dokholyan NV., Riordan JR., Brouillette CG., Hunt JF.**

Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator

*Journal of Biological Chemistry* 2018; 293: 17685 - 17704

**Zulueta A., Colombo M., Peli V., Falleni M., Tosi D., Ricciardi M., Baisi A., Bulfamante G., Chiaramonte R., Caretti A.**

Lung mesenchymal stem cells-derived extracellular vesicles attenuate the inflammatory profile of Cystic Fibrosis epithelial cells

*Cellular Signalling* 2018; 51: 110 - 118

## CFTR

**Adam D., Bilodeau C., Sognigbe L., Maille E., Ruffin M., Brochiero E.**

CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of *Pseudomonas aeruginosa* exoproducts

*Journal of Cystic Fibrosis* 2018; 17: 705 - 714

**Chaudary N.**

Triplet CFTR modulators: future prospects for treatment of cystic fibrosis

*Therapeutics and Clinical Risk Management* 2018; 14: 2375 - 2383

**Fay JF., Aleksandrov LA., Jensen TJ., Cui LYL., Kousouros JN., He LH., Aleksandrov AA., Gingerich DS., Riordan JR., Chen JZ.**

Cryo-EM Visualization of an Active High Open Probability CFTR Anion Channel

*Biochemistry* 2018; 57: 6234 - 6246

**Froux L., Billet A., Becq F.**

Modulating the cystic fibrosis transmembrane regulator and the development of new precision drugs

*Expert Review of Precision Medicine and Drug Development* 2018; 3: 357 - 370

**Fukuda R., Okiyoneda T.**

Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer

*Frontiers in Pharmacology* 2018; 9: ArNo: 1100

**Gees M., Musch S., Van der Plas S., Wesse AS., Vandeveldel A., Verdonck K., Mammoliti O., Hwang TC., Sonck K., Stouten P., Swensen AM., Jans M., Van der Schueren J., Nelles L., Andrews M., Conrath K.**

Identification and Characterization of Novel CFTR Potentiators

*Frontiers in Pharmacology* 2018; 9: ArNo: 1221

**Gentsch M., Cholon DM., Quinney NL., Boyles SE., Martino MEB., Ribeiro CMP.**

The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model

*European Respiratory Journal* 2018; 52: 6:1801133

**Hoffmann B., Elbahnsi A., Lehn P., Decout JL., Pietrucci F., Mornon JP., Callebaut I.**

Combining theoretical and experimental data to decipher CFTR 3D structures and functions

*Cellular and Molecular Life Sciences* 2018; 75: 3829 - 3855

**Kerschner JL., Ghosh S., Paranjapye A., Cosme WR., Audrezet MP., Nakakuki M., Ishiguro H., Ferec C., Rommens J., Harris A.** Screening for Regulatory Variants in 460 kb Encompassing the CFTR Locus in Cystic Fibrosis Patients

*Journal of Molecular Diagnostics* 2019; 21: 70 - 80

**Kleme ML., Sane A., Garofalo C., Seidman E., Brochiero E., Berthiaume Y., Levy E.**

CFTR Deletion Confers Mitochondrial Dysfunction and Disrupts Lipid Homeostasis in Intestinal Epithelial Cells

*Nutrients* 2018; 10: 7:836

**Langron E., Prins S., Vergani P.**

Potiation of the cystic fibrosis transmembrane conductance regulator by VX-770 involves stabilization of the pre-hydrolytic, O-1 state

*British Journal of Pharmacology* 2018; 175: 3990 - 4002

**Li WJ., Wang CY., Peng XN., Zhang HW., Huang HB., Liu HM.** CFTR inhibits the invasion and growth of esophageal cancer cells by inhibiting the expression of NF-kappa B

*Cell Biology International* 2018; 42: 1680 - 1687

**Liu Q., Sabirzhanova L., Yanda MK., Bergbower EAS., Boinot C., Guggino WB., Cebotaru L.**

Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome

*Journal of Cystic Fibrosis* 2018; 17: 582 - 594

**Madacsy T., Pallagi P., Maleth J.**

Cystic Fibrosis of the Pancreas: The Role of CFTR Channel in the Regulation of Intracellular Ca<sup>2+</sup> Signaling and Mitochondrial Function in the Exocrine Pancreas

*Frontiers in Physiology* 2018; 9: ArNo: 1585

**Matthes E., Goepf J., Martini C., Shan JJ., Liao J., Thomas DY., Hanrahan JW.**

Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine

*Frontiers in Pharmacology* 2018; 9: ArNo: 1490

**Meng X., Clews J., Martin ER., Ciuta AD., Ford RC.**

The structural basis of cystic fibrosis

*Biochemical Society Transactions* 2018; 46: 1093 - 1098

**Nikiforova AI., Abramov DD., Zobkova GY., Goriainova AV., Semykin SY., Shubina J., Donnikov AE., Trofimov DY.**

Detection of CFTR mutations in children with cystic fibrosis

*Bulletin of Russian State Medical University* 2018; : 34 - 40

**Odera M., Furuta T., Sohma Y., Sakurai M.**

Molecular dynamics simulation study on the structural instability of the most common cystic fibrosis-associated mutant Delta F508-CFTR

*Biophysics and Physicobiology* 2018; 15: 33 - 44

**Pankow S., Bamberger C., Yates JR.**

A posttranslational modification code for CFTR maturation is altered in cystic fibrosis

*Science Signaling* 2019; 12: 562:7984

**Pibiri I., Lentini L., Melfi R., Tutone M., Baldassano S., Galluzzo PR., Di Leonardo A., Pace A.**

Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs

*European Journal of Medicinal Chemistry* 2018; 159: 126 - 142

**Ramli NSK., Giribabu N., Salleh N.**

Testosterone enhances expression and functional activity of epithelial sodium channel (ENaC), cystic fibrosis transmembrane regulator (CFTR) and sodium hydrogen exchanger (NHE) in vas deferens of sex-steroid deficient male rats

*Steroids* 2018; 138: 117 - 133

**Sabirzhanova I., Boinot C., Guggino WB., Cebotaru L.**  
Syntaxin 8 and the Endoplasmic Reticulum Processing of Delta F508-CFTR

*Cellular Physiology and Biochemistry* 2018; 51: 1489 - 1499

**Sharma N., Evans TA., Pellicore MJ., Davis E., Aksit MA., McCague AF., Joynt AT., Lu ZZ., Han ST., Anzmann AF., Lam ATN., Thaxton A., West N., Merlo C., Gottschalk LB., Raraigh KS., Sosnay PR., Cotton CU., Cutting GR.**

Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis  
*PLoS Genetics* 2018; 14: 11:e1007723

**Teerapunchareon K., Wells JM., Raju SV., Raraigh KS., Aksit MA., Cutting GR., Rasmussen L., Nath PH., Bhatt SP., Solomon GM., Dransfield MT., Rowe SM.**

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction and Radiographic Bronchiectasis in Current and Former Smokers: A Cross-Sectional Study  
*Annals of the American Thoracic Society* 2019; 16: 150 - 153

**Werlin S., Scotet V., Uguen K., Audrezet MP., Cohen M., Yaakov Y., Safadi R., Ilan Y., Konikoff F., Galun E., Mizrahi M., Slae M., Sayag S., Cohen-Cymerberknob M., Wilschanski M., Ferec C.**  
Primary sclerosing cholangitis is associated with abnormalities in CFTR

*Journal of Cystic Fibrosis* 2018; 17: 666 - 671

**Zhang Z., Liu FY., Chen J.**

Molecular structure of the ATP-bound, phosphorylated human CFTR  
*Proceedings of the National Academy of Sciences of the United States* 2018; 115: 12757 - 12762

**Zhang JY., Yu YC., Yeh JT., Hwang TC.**

Functional characterization reveals that zebrafish CFTR prefers to occupy closed channel conformations  
*PLoS One* 2018; 13: 12:e0209862

## Clinical

**Armiento R., Ranganathan SC., Harrison J.**

The implementation of a cystic fibrosis annual review process in a tertiary paediatric hospital  
*Archives of Disease in Childhood-Education and Practice Edition* 2018; 103: 241 - 243

**Breuer O., Caudri D., Stick S., Turkovic L.**

Predicting disease progression in cystic fibrosis  
*Expert Review of Respiratory Medicine* 2018; 12: 905 - 917

**Chi DL., Rosenfeld M., Mancil L., Chung WO., Presland RB., Sarvas E., Rothen M., Alkhateeb A., McNamara S., Genatossio A., Virella-Lowell I., Milla C., Scott J.**

Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6-20 years: A pilot study  
*Journal of Cystic Fibrosis* 2018; 17: 747 - 759

**Corriveau S., Sykes J., Stephenson AL.**

Cystic fibrosis survival: the changing epidemiology  
*Current Opinion in Pulmonary Medicine* 2018; 24: 574 - 578

**de Winter-de Groot KM., Janssens HM., van Uum RT., Dekkers JF., Berkers G., Vonk A., Kruisselbrink E., Oppelaar H., Vries R., Clevers H., Houwen RHJ., Escher JC., Elias SG., de Jonge HR., de Rijke YB., Tiddens HAWM., van der Ent CK., et al**  
Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function  
*European Respiratory Journal* 2018; 52: 3:1702529

**Dechecchi MC., Tamanini A., Cabrini G.**

Molecular basis of cystic fibrosis: from bench to bedside  
*Annals of Translational Medicine* 2018; 6: 17:334

**dos Santos ALM., Santos HD., Nogueira MB., Tavora HTO., da Cunha MDJP., Seixas RBP., Monte LDV., de Carvalho E.**

Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents  
*Pediatric Gastroenterology Hepatology & Nutrition* 2018; 21: 306 - 314

**Edwards TC., Emerson J., Genatossio A., McNamara S., Goss C., Patrick DL., Onchiri F., Rosenfeld M.**

Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0-11 years  
*Journal of Cystic Fibrosis* 2018; 17: 680 - 686

**Guo XB., Liu KQ., Liu YP., Situ YS., Tian XL., Xu KF., Zhang X.**  
Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases

*Orphanet Journal of Rare Diseases* 2018; 13: ArNo: 224

**Hoch H., Sontag MK., Scarbro S., Juarez-Colunga E., McLean C., Kempe A., Sagel SD.**

Clinical outcomes in US infants with cystic fibrosis from 2001 to 2012  
*Pediatric Pulmonology* 2018; 53: 1492 - 1497

**Jessula S., Van den Hof M., Mateos-Corral D., Mills J., Davies D., Romao RLP.**

Predictors for surgical intervention and surgical outcomes in neonates with cystic fibrosis  
*Journal of Pediatric Surgery* 2018; 53: 2150 - 2154

**Kern-Goldberger AS., Hessels AJ., Saiman L., Quittell LM.**

Understanding of safety monitoring in clinical trials by individuals with CF or their parents: A qualitative analysis  
*Journal of Cystic Fibrosis* 2018; 17: 736 - 741

**Rho J., Ahn C., Gao A., Sawicki GS., Keller A., Jain R.**

Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States A National and Regional Cohort Study  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1055 - 1063

**Ruffles TJC., Black R., Nicholls W., Laing B., Isles A.**

Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstacles  
*Frontiers in Pediatrics* 2018; 6: ArNo: 245

**Saavedra MT., Quon BS., Faino A., Caceres SM., Poch KR., Sanders LA., Malcolm KC., Nichols DP., Sagel SD., Taylor-Cousar JL., Leach SM., Strand M., Nick JA.**

Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study  
*Annals of the American Thoracic Society* 2018; 15: 589 - 598

**Terlizzi V., Lucarelli M., Salvatore D., Angioni A., Bisogno A., Braggion C., Buzzetti R., Carnovale V., Casciaro R., Castaldo G., Cirilli N., Iollura M., Colombo C., Di Lullo AM., Elce A., Lucidi V., Madarena E., Padoan R., et al**

Clinical expression of cystic fibrosis in a large cohort of Italian siblings  
*BMC Pulmonary Medicine* 2018; 18: ArNo: 196

**Trigo-Salado C., Leo-Carnerero E., de-la-Cruz-Ramirez D.**

Crohn's disease and cystic fibrosis: there is still a lot to learn  
*Revista Espanola de Enfermedades Digestivas* 2018; 110: 836

**Wood ME., Stockwell RE., Bell SC.**

Use of Masks in Patients with Cystic Fibrosis Reply  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1589 - 1590

**Zuckerman JB., Saiman L.**

Use of Masks in Patients with Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1588 - 1589

## Databases & Registries

**Desai S., Wong H., Sykes J., Stephenson AL., Singer J., Quon BS.**  
Clinical Characteristics and Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis Analysis of the Canadian CF Registry  
*Annals of the American Thoracic Society* 2018; 15: 1177 - 1185

**Keogh RH., Seaman SR., Barrett JK., Taylor-Robinson D., Szczesniak R.**

Dynamic Prediction of Survival in Cystic Fibrosis A Landmarking Analysis Using UK Patient Registry Data  
*Epidemiology* 2019; 30: 29 - 37



**McIntyre K., Bertrand DP., Rault G.**

Using registry data to improve quality of care  
*Journal of Cystic Fibrosis* 2018; 17: 566 - 572

**Zolin A., Bossi A., Cirilli N., Kashirskaya N., Padoan R.**

Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry  
*International Journal of Environmental Research and Public Health* 2018; 15: 9:2020

## Diabetes

**Banavath LN., Kumar R., Dayal D., Yadav J., Sachdeva N., Mathew JL., Vaidya PC., Singh M.**

Glucose intolerance in children with cystic fibrosis: a developing country's perspective  
*Journal of Pediatric Endocrinology & Metabolism* 2018; 31: 1139 - 1146

**Bechtold SM., Rohrer TR., Raile K., Hofer S., Thon A., Boettcher C., Konrad K., Pozza RD., Bollow E., Holl RW.**

Diabetes mellitus in pediatric solid organ recipients without and with cystic fibrosis: An analysis from the German-Austrian diabetes database (Diabetes Patienten Verlaufsdokumentation)  
*Pediatric Diabetes* 2018; 19: 1191 - 1197

**Birch L., Lithander FE., Hewer SL., Harriman K., Hamilton-Shield J., Perry R.**

Dietary interventions for managing glucose abnormalities in cystic fibrosis: a systematic review protocol  
*Systematic Reviews* 2018; 7: ArNo: 98

**Brugha R., Wright M., Nolan S., Bridges N., Carr SB.**

Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 791 - 797

**Chan CL., Vigers T., Pyle L., Zeitler PS., Sagel SD., Nadeau KJ.**  
Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline  
*Journal of Cystic Fibrosis* 2018; 17: 783 - 790

**Colombo C., Alicandro G., Gambazza S., Mileto P., Mari A., Grespan E., Nazzari E., Russo MC., Battezzati A.**

Ventilation inhomogeneity is associated with OGTT-derived insulin secretory defects in cystic fibrosis  
*Pediatric Pulmonology* 2019; 54: 141 - 149

**Frost F., Dyce P., Nazareth D., Malone V., Walshaw MJ.**

Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes  
*Journal of Cystic Fibrosis* 2018; 17: 798 - 803

**Moran A., Pillay K., Becker D., Granados A., Hameed S., Acerini CL.**

ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents  
*Pediatric Diabetes* 2018; 19:

**Nyirjesy SC., Sheikh S., Hadjiliadis D., De Leon DD., Peleckis AJ., Eiel JN., Kubrak C., Stefanovski D., Rubenstein RC., Rickels MR., Kelly A.**

beta-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose  $\geq$  155 mg/dL  
*Pediatric Diabetes* 2018; 19: 1173 - 1182

## Diagnosis

**Brown KL., Flume PA.**

Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis  
*Journal of Genetic Counseling* 2018; 27: 1049 - 1054

**Gomez CCS., Marson FAL., Servidoni MF., Ribeiro AF., Ribeiro MAGO., Gama VAL., Costa ET., Ribeiro JD., Vieira FU.**

Evaluation of continuous constant current and continuous pulsed current in sweat induction for cystic fibrosis diagnosis  
*BMC Pulmonary Medicine* 2018; 18: ArNo: 153

**Gonzalez-Andrade F.**

Standardized clinical criteria and sweat test combined as a tool to diagnose Cystic Fibrosis  
*Heliyon* 2018; 4: 12:e01050

**Kassal P., Steinberg MD., Horak E., Steinberg IM.**

Wireless fluorimeter for mobile and low cost chemical sensing: A paper based chloride assay  
*Sensors and Actuators B-chemical* 2018; 275: 230 - 236

**Kim SB., Lee K., Raj MS., Lee B., Reeder JT., Koo J., Hourlier-Fargette A., Bandodkar AJ., Won SM., Sekine Y., Choi J., Zhang Y., Yoon J., Kim BH., Yun Y., Lee S., Shin J., Kim J., Ghaffari R., Rogers JA.**

Soft, Skin-Interfaced Microfluidic Systems with Wireless, Battery-Free Electronics for Digital, Real-Time Tracking of Sweat Loss and Electrolyte Composition  
*Small* 2018; 14: 45:1802876

**Lemke J., Gartner M., Kemen C., Hoger PH.**

Clinical Diagnosis of Mucoviscidosis in false-negative Mucoviscidosis Neonatal Screening  
*Monatsschrift Kinderheilkunde* 2018; 166: 889 - 893

**Moser C., Thomsen TR., Hoiby N.**

Next generation microbiology and cystic fibrosis diagnostics: are we there yet?  
*Current Opinion in Pulmonary Medicine* 2018; 24: 599 - 605

**Qiu LR., Yang FJ., He YH., Yuan HQ., Zhou JH.**

Clinical characterization and diagnosis of cystic fibrosis through exome sequencing in Chinese infants with Bartter-syndrome-like hypokalemia alkalosis  
*Frontiers of Medicine* 2018; 12: 550 - 558

**Wienczek JR., Lo SF.**

Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era  
*Clinical Chemistry* 2018; 64: 898 - 908

## Epidemiology

**Adyan TA., Stepanova AA., Krasovskiy SA., Polyakov AV.**

Updating Diagnostic Spectrum of Recurring CFTR Mutations  
*Russian Journal of Genetics* 2018; 54: 1235 - 1244

**Al-Sadeq D., Abunada T., Dalloul R., Fahad S., Taleb S., Aljassim K., Al Hamed FA., Zayed H.**

Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review  
*Respirology* 2019; 24: 127 - 136

**da Rosa KM., de Lima ED., Machado CC., Rispoli T., Silveira VD., Ongaratto R., Comaru T., Pinto LA.**

Genetic and phenotypic characteristics of children and adolescents with cystic fibrosis in Southern Brazil  
*Jornal Brasileiro de Pneumologia* 2018; 44: 498 - 504

**Puppo H., Von Oetinger A., Benz E., Torres-Castro R., Zagolin M., Boza ML., Astorga L., Bozzo R., Jorquera P., Kogan R., Perillan J.**

Characterization of the physical capacity in children of the Chilean National Program of Cystic Fibrosis  
*Revista Chilena de Pediatría-chile* 2018; 89: 638 - 643

**Zampoli M., Morrow B., Masekela R., Calligaro G., Baird C., Klugman S., Mer M., Gebers P., Els C., Richards D., Egner J., Walters S., Morrison J., Terblanche A., Wolf A., Dunn A.**

Cystic fibrosis: What's new in South Africa in 2019  
*SAMJ South African Medical Journal* 2019; 109: 16 - 19

## Exercise

**Abdelbasset WK., Soliman GS., Elshehawey AA., Alrawaili SM.**

Exercise capacity and muscle fatigability alterations following a progressive maximal exercise of lower extremities in children with cystic fibrosis  
*African Health Sciences* 2018; 18: 1236 - 1242

**Chen JJ., Cooper DM., Haddad F., Sladkey A., Nussbaum E., Radom-Aizik S.**

Tele-Exercise as a Promising Tool to Promote Exercise in Children With Cystic Fibrosis  
*Frontiers in Public Health* 2018; 6: ArNo: 269

**Cox NS., Holland AE.**

Current perspectives of physical activity in cystic fibrosis  
*Expert Review of Respiratory Medicine* 2019; 13: 13 - 22

**Gambazza S., Turrin V., Speziali C., Brivio A., Valmarana L., Carta F., Bulfamante AMC., Colombo C.**

Expiratory muscle strength and functional exercise tolerance in adults with cystic fibrosis: a cross-sectional study  
*Physiotherapy Research International* 2018; 23: 4:e1720

**Punter RMG., Moreno RMG., Espinosa EV., Soriano JB., Pastor MT., Zamora E., Valenzuela C., Onso TA., Castillo EG., Ancochea J.**

Desaturations During 6-Minute Walk Test and Predicting Nocturnal Desaturations in Adult Subjects With Cystic Fibrosis  
*Respiratory Care* 2019; 64: 48 - 54

**Sawyer A., Cavalheri V., Jenkins S., Wood J., Cecins N., Singh B., Hill K.**

Effects of high intensity interval training on exercise capacity in people with cystic fibrosis: study protocol for a randomised controlled trial

*BMC Sports Science Medicine and Rehabilitation* 2018; 10: ArNo: 19

**Sheppard E., Chang K., Cotton J., Gashgarian S., Slack D., Wu K., Michalski A., Fox P., Stephenson AL., Mathur S.**

Functional Tests of Leg Muscle Strength and Power in Adults With Cystic Fibrosis

*Respiratory Care* 2019; 64: 40 - 47

**Ward N., Stiller K., Holland AE.**

Exercise is commonly used as a substitute for traditional airway clearance techniques by adults with cystic fibrosis in Australia: a survey

*Journal of Physiotherapy* 2019; 65: 43 - 50

**Urquhart DS., Saynor ZL.**

Exercise testing in cystic fibrosis: Who and why?

*Paediatric Respiratory Reviews* 2018; 27: 28 - 32

**Vendrusculo FM., Johnstone Z., Dhouieb E., Donadio MVF., Cunningham S., Urquhart DS.**

Airway clearance physiotherapy improves ventilatory dynamics during exercise in patients with cystic fibrosis: a pilot study  
*Archives of Disease in Childhood* 2019; 104: 37 - 42

## Gastroenterology

**Cory M., Moin AM., Moran A., Rizza RA., Butler PC., Dhawan S., Butler AE.**

An Increase in Chromogranin A-Positive, Hormone-Negative Endocrine Cells in Pancreas in Cystic Fibrosis  
*Journal of the Endocrine Society* 2018; 2: 1058 - 1066

**Desai CS., Vonderau JS., McCall R., Khan KM., Baron TH.**

Pancreatic cystosis in patients with cystic fibrosis: A qualitative systematic review  
*Pancreatology* 2018; 18: 700 - 704

**Green J., Carroll W., Gilchrist FJ.**

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis

*Cochrane Database of Systematic Reviews* 2018; : 8:CD012798

**Nanavati SM., Patel H., Melki G., Kumar V., Milman E., Michael P., Volfson A.**

Acute Appendicitis Masquerading Distal Intestinal Obstruction Syndrome in Adult Cystic Fibrosis

*Case Reports in Gastrointestinal Medicine* 2018; : ArNo: 8475060

**Platt KD., Sondhi AR., DiMagno MJ.**

Pancreatic Cancer: A Rare Cause of Abdominal Pain in Severe Cystic Fibrosis

*Pancreas* 2019; 48: e3 - e4

**Stevens J., Wyatt C., Brown P., Patel D., Grujic D., Freedman SD.**

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding

*Journal of Pediatric Gastroenterology and Nutrition* 2018; 67: 527 - 532

**Yamashiro KJ., Galganski LA., Hirose S., Stark RA.**

Midgut volvulus and complex meconium peritonitis in a fetus with undiagnosed cystic fibrosis

*Journal of Pediatric Surgery Case Reports* 2019; 40: 26 - 29

## Gene Therapy

**Cooney AL., McCray PB., Sinn PL.**

Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward  
*Genes* 2018; 9: 11:538

**Hague AKMA., Dewerth A., Antony JS., Riethmuller J., Schweizer GR., Weinmann P., Latifi N., Yasar H., Pedemonte N., Sondo E., Weidensee B., Ralhan A., Laval J., Schlegel P., Seitz C., Loretz B., Lehr CM., Handgretinger R., et al**

Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

*Scientific Reports* 2018; 8: ArNo: 16776

**Taylor-Alexander S., Addison C.**

Building for Biology: A Gene Therapy Trial Infrastructure  
*Engaging Science Technology and Society* 2017; 3: 332 - 350

## General Review

**Doull I.**

Cystic fibrosis papers of the year 2017

*Paediatric Respiratory Reviews* 2018; 27: 2 - 5

## Genetics

**DeStefano S., Gees M., Hwang TC.**

Physiological and pharmacological characterization of the N1303K mutant CFTR

*Journal of Cystic Fibrosis* 2018; 17: 573 - 581

**Farrell P., Ferec C., Macek M., Frischer T., Renner S., Riss K., Barton D., Repetto T., Tzetis M., Giteau K., Duno M., Rogers M., Levy H., Sahbatou M., Fichou Y., Le Marechal C., Genin E.**

Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis

*European Journal of Human Genetics* 2018; 26: 1832 - 1839

**Lin ZW., Thorenoor N., Wu RL., DiAngelo SL., Ye MX., Thomas NJ., Liao XJ., Lin TR., Warren S., Floros J.**

Genetic Association of Pulmonary Surfactant Protein Genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis  
*Frontiers in Immunology* 2018; 9: ArNo: 2256

**Mota LR., de Melo VM., de Castro LL., Garcia DF., Terse-Ramos R., Toralles MBP., de Lima RLLF., Souza EL.**

Description of rare mutations and a novel variant in Brazilian patients with Cystic Fibrosis: a case series from a referral center in the Bahia State

*Molecular Biology Reports* 2018; 45: 2045 - 2051

**Salvatore D., Padoan R., Buzzetti R., Amato A., Giordani B., Ferrari G., Majo F.**

Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry

*Pediatric Pulmonology* 2019; 54: 150 - 157

**Smith DJ., Klein K., Hartel G., Wainwright CE., Bell SC., Anderson GJ., Reid DW.**

Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis

*Gene* 2019; 683: 12 - 17

**Yang B., Wang X., Zhang W., Li HJ., Wang BB.**  
Compound heterozygous mutations in CFTR causing CBAVD in Chinese pedigrees  
*Molecular Genetics & Genomic Medicine* 2018; 6: 1097 - 1103

**Yokoyama E., Chavez-Saldana M., Orozco L., Cuevas F., Lezana JL., Viguera-Villasenor RM., Rojas-Castaneda JC., Landero DA.**

Influence of SNPs in Genes that Modulate Lung Disease Severity in a Group of Mexican Patients with Cystic Fibrosis  
*Archives of Medical Research* 2018; 49: 18 - 26

**Zou WB., Tang XY., Zhou DZ., Qian YY., Hu LH., Yu FF., Yu D., Wu H., Deng SJ., Lin JH., Zhao AJ., Zhao ZH., Wu HY., Zhu JH., Qian W., Wang L., Xin L., Wang MJ., Wang LJ., Fang X., He L., Masson E., Cooper DN., Ferec C., Li ZS.**

SPINK1, PRSS1, CTSC, and CFTR Genotypes Influence Disease Onset and Clinical Outcomes in Chronic Pancreatitis  
*Clinical and Translational Gastroenterology* 2018; 9: ArNo: 204

## Growth & Development

**Callela P., Valerio G., Brodli M., Donini LM., Siervo M.**  
Cystic fibrosis, body composition, and health outcomes: a systematic review  
*Nutrition* 2018; 55-56: 131 - 139

**Paulina BM., Balboa P., Torrejon C., Bozzo R., Boza ML., Contreras I., Jorquera P., Astorga L., Weisstaub G.**  
Bone mineral density, lung function, vitamin D and body composition in children and adolescents with cystic fibrosis: a multicenter study  
*Nutricion Hospitalaria* 2018; 35: 789 - 795

**Thaker V., Carter B., Putman M.**  
Recombinant growth hormone therapy for cystic fibrosis in children and young adults  
*Cochrane Database of Systematic Reviews* 2018; : 12:CD008901

## Immunology & Inflammation

**Bianconi I., Alcalá-Franco B., Scarselli M., Dalsass M., Buccato S., Colaprico A., Marchi S., Masignani V., Bragonzi A.**  
Genome-Based Approach Delivers Vaccine Candidates Against *Pseudomonas aeruginosa*  
*Frontiers in Immunology* 2019; 9: ArNo: 3021

**Chandler JD., Margaroli C., Horati H., Kilgore MB., Veltman M., Liu HK., Taurone AJ., Peng LM., Gugliani L., Uppal K., Go YM., Tiddens HAWM., Scholte BJ., Tirouvanziam R., Jones DP., Janssens HM.**  
Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease  
*European Respiratory Journal* 2018; 52: 4:1801118

**Chen YDH., Armstrong DA., Salas LA., Hazlett HF., Nymon AB., Dessaint JA., Aridgides DS., Mellinger DL., Liu XY., Christensen BC., Ashare A.**  
Genome-wide DNA methylation profiling shows a distinct epigenetic signature associated with lung macrophages in cystic fibrosis  
*Clinical Epigenetics* 2018; 10: ArNo: 152

**Coriati A., Masse C., Menard A., Bouvet GF., Berthiaume Y.**  
Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis  
*Inflammation* 2018; 41: 1631 - 1639

**da Cunha ALP., da Costa ACC., Vasconcelos Z., Do Carmo MDT., Chaves CRMD.**  
Fatty acid profile in erythrocytes associated with serum cytokines in pediatric cystic fibrosis patients  
*Revista de Nutricao-brazilian Journal of Nutrition* 2018; 31: 455 - 466

**Elborn JS., Ahuja S., Springman E., Mershon J., Grosswald R., Rowe SM.**  
EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics  
*Contemporary Clinical Trials* 2018; 72: 86 - 94

**Forrest OA., Ingersoll SA., Preininger MK., Laval J., Limoli DH., Brown MR., Lee FE., Bedi B., Sadikot RT., Goldberg JB., Tangpricha V., Gaggari A., Tirouvanziam R.**  
Frontline Science: Pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis  
*Journal of Leukocyte Biology* 2018; 104: 665 - 675

**Gamaletsou MN., Hayes G., Harris C., Brock J., Muldoon EG., Denning DW.**  
F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis  
*Journal of Asthma* 2018; 55: 837 - 843

**Guillon A., Brea D., Luczka E., Herve V., Hasanat S., Thorey C., Perez-Cruz M., Hordeaux J., Mankikian J., Gosset P., Coraux C., Si-Tahar M.**  
Inactivation of the interleukin-22 pathway in the airways of cystic fibrosis patients  
*Cytokine* 2019; 113: 470 - 474

**Gomez C., Carsin A., Gouita M., Reynaud-Gaubert M., Dubus JC., Mege JL., Ranque S., Vitte J.**  
Mast cell tryptase changes with *Aspergillus fumigatus* - Host crosstalk in cystic fibrosis patients  
*Journal of Cystic Fibrosis* 2018; 17: 631 - 635

**Kathriachchige G., Daley C., Pallin M., Polkinghorne K., King PT.**  
C-reactive protein levels in acute respiratory exacerbations of cystic fibrosis  
*Internal Medicine Journal* 2018; 48: 1392 - 1395

**Merakou C., Schaeffers MM., Priebe GP.**  
Progress Toward the Elusive *Pseudomonas aeruginosa* Vaccine  
*Surgical Infections* 2018; 35: 499 - 507

**Montgomery ST., Dittrich AS., Garratt LW., Turkovic L., Frey DL., Stick SM., Mall MA., Kicic A.**  
Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 715 - 722

**Philippe R., Urbach V.**  
Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis  
*International Journal of Molecular Sciences* 2018; 19: 10:2865

**Rimessi A., Bezzeri V., Salvatori F., Tamanini A., Nigro F., Dececchi MC., Santangelo A., Prandini P., Munari S., Provezza L., de Loubresse NG., Muller J., Ribeiro CMP., Lippi G., Gambari R., Pinton P., Cabrini G.**  
PLCB3 Loss of Function Reduces *Pseudomonas aeruginosa*-Dependent IL-8 Release in Cystic Fibrosis  
*American Journal of Respiratory Cell and Molecular Biology* 2018; 59: 428 - 436

**Robledo-Avila FH., Ruiz-Rosado JD., Brockman KL., Kopp BT., Amer AO., McCoy K., Bakaletz LO., Partida-Sanchez S.**  
Dysregulated Calcium Homeostasis in Cystic Fibrosis Neutrophils Leads to Deficient Antimicrobial Responses  
*Journal of Immunology* 2018; 201: 2016 - 2027

**Roesch EA., Nichols DP., Chmiel JF.**  
Inflammation in cystic fibrosis: An update  
*Pediatric Pulmonology* 2018; 53:

**Velard F., Jourdain ML., Abdallah D., Jacquot J., Ronan N., McCarthy Y., Flanagan E., Plant B.**  
Overexpression of RANK and M-CSFR in Monocytes of G551D-Bearing Patients with Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 968 - 970

**Wagner CE., Wheeler KM., Ribbeck K.**  
Mucins and Their Role in Shaping the Functions of Mucus Barriers  
*Annual Review of Cell and Developmental Biology*, Vol 34 2018; 34: 189 - 215

## Liver Disease

**Calvopina DA., Chatfield MD., Weis A., Coleman MA., Fernandez-Rojo MA., Noble C., Ramm LE., Leung DH., Lewindon PJ., Ramm GA.**

MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis  
*Hepatology* 2018; 68: 2301 - 2316

**Davison S.**

Assessment of liver disease in cystic fibrosis  
*Paediatric Respiratory Reviews* 2018; 27: 24 - 27

**Klymenko VA., Piontkovska OV., Pasichnyk OV., Drobova NM., Yanovska KO., Bevz SL., Sindieieva NT.**

A clinical case report of cystic fibrosis and liver cirrhosis in a child  
*Zaporozhye Medical Journal* 2018; : 739 - 742

**Nascimento FD., Sena NA., Ferreira TD., Marques CDF., Silva LR., Souza EL.**

Hepatobiliary disease in children and adolescents with cystic fibrosis  
*Jornal de Pediatria* 2018; 94: 504 - 510

**Polineni D., Piccorelli AV., Hannah WB., Dalrymple SN., Pace RG., Durie PR., Ling SC., Knowles MR., Stonebraker JR.**

Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population  
*PLoS One* 2018; 13: 10:e0205257

**Ruzman L., Mikolasevic I., Dekanic KB., Milic S., Palcevski G.**  
Advances in diagnosis of chronic liver diseases in pediatric patients  
*World Journal of Pediatrics* 2018; 14: 541 - 547

**Wong A., Cheung B., Nejad C., Gantier M., Graudins A.**

Hepatotoxicity after paracetamol overdose in a patient with cystic fibrosis despite early acetylcysteine and utility of microRNA to predict hepatotoxicity  
*Clinical Toxicology* 2018; 56: 904 - 906

## Microbiology

**Acosta N., Heirali A., Somayaji R., Surette MG., Workentine ML., Sibley CD., Rabin HR., Parkins MD.**

Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis  
*Thorax* 2018; 73: 1016 - 1025

**Akil N., Muhlebach MS.**

Biology and management of methicillin resistant *Staphylococcus aureus* in cystic fibrosis  
*Pediatric Pulmonology* 2018; 53:

**Al Ahmar R., Kirby BD., Yu HWD.**

Pyrimidine Biosynthesis Regulates the Small-Colony Variant and Mucooidy in *Pseudomonas aeruginosa* through Sigma Factor Competition  
*Journal of Bacteriology* 2019; 201: 1:e00575-18

**Alikhani Z., Salouti M., Ardestani MS.**

Synthesis and immunological evaluation of a nanovaccine based on PLGA nanoparticles and alginate antigen against infections caused by *Pseudomonas aeruginosa*  
*Biomedical Physics & Engineering Express* 2018; 4: 4:UNSP 045016

**Atkin SD., Abid S., Foster M., Bose M., Keller A., Holloway R., Sader HS., Greenberg DE., Finklea JD., Castanheira M., Jain R.**

Multidrug-resistant *Pseudomonas aeruginosa* from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam  
*Infection and Drug Resistance* 2018; 11: 1499 - 1510

**Bara JJ., Matson Z., Remold SK.**

Life in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen *Pseudomonas aeruginosa*  
*Royal Society Open Science* 2018; 5: 9:180623

**Barnes LA., Gaillard PR., Menk JS., Wey AR., Regelman WE., Demirel N.**

Decreased *Pseudomonas aeruginosa* detection in children after separation of pediatric from adult cystic fibrosis clinics: A single center experience  
*Pediatric Pulmonology* 2018; 53: 1604 - 1610

**Becka SA., Zeiser ET., Barnes MD., Taracila MA., Nguyen K., Singh I., Sutton GG., LiPuma JJ., Fouts DE., Papp-Wallace KM.**  
Characterization of the AmpC beta-Lactamase from *Burkholderia multivorans*

*Antimicrobial Agents and Chemotherapy* 2018; 62: 10:e01140-18

**Bell J., Moore JE., Millar BC.**

Cleaning of inpatient nebulizer devices in cystic fibrosis patients: the urgent need for universal guidelines  
*Journal of Hospital Infection* 2018; 100: E64 - E66

**Blanchard AC., Rooney AM., Yau Y., Zhang Y., Stapleton PJ., Horton E., Klingel M., Stanojevic S., Ratjen F., Coburn B., Waters V.**

Early detection using qPCR of *Pseudomonas aeruginosa* infection in children with cystic fibrosis undergoing eradication treatment  
*Journal of Cystic Fibrosis* 2018; 17: 723 - 728

**Bianconi I., D'Arcangelo S., Esposito A., Benedet M., Piffer E., Dinnella G., Gualdi P., Schinella M., Baldo E., Donati C., Jousson O.**

Persistence and Microevolution of *Pseudomonas aeruginosa* in the Cystic Fibrosis Lung: A Single-Patient Longitudinal Genomic Study  
*Frontiers in Microbiology* 2019; 9: ArNo: 3242

**Caballero JD., Clark ST., Wang PW., Donaldson SL., Coburn B., Tullis DE., Yau YCW., Waters VJ., Hwang DM., Guttman DS.**

A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in *Burkholderia multivorans*  
*PLoS Pathogens* 2018; 14: 12:e1007453

**Cacador NC., Capizzani CPD., Torres LAGMM., Galetti R., Ciofu O., Darini ALD., Flefby N.**

Adaptation of *Pseudomonas aeruginosa* to the chronic phenotype by mutations in the algTmucABD operon in isolates from Brazilian cystic fibrosis patients  
*PLoS One* 2018; 13: 11:e0208013

**Caverly LJ., LiPuma JJ.**

Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice  
*Expert Review of Respiratory Medicine* 2018; 12: 857 - 865

**Chalhoub H., Saenz Y., Nichols WW., Tulkens PM., Van Bambeke F.**

Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in *Pseudomonas aeruginosa* isolated from patients suffering from cystic fibrosis  
*International Journal of Antimicrobial Agents* 2018; 52: 697 - 701

**Cipolla L., Rocca F., Martinez C., Aguerre L., Barrios R., Prieto M.**

Prevalence of *Burkholderia cepacia* complex species in cystic fibrosis patients in Argentina during the period 2011-2015  
*Enfermedades Infecciosas Y Microbiologia Clinica* 2018; 36: 431 - 434

**Crull MR., Somayaji R., Ramos KJ., Caldwell E., Mayer-Hamblett N., Aitken ML., Nichols DP., Rowhani-Rahbar A., Goss CH.**

Changing Rates of Chronic *Pseudomonas aeruginosa* Infections in Cystic Fibrosis: A Population-Based Cohort Study  
*Clinical Infectious Diseases* 2018; 67: 1089 - 1095

**De Baets F., De Keyser L., Van Daele S., Schelstraete P., Van Biervliet S., Van Braeckel E., Thomas M., Wanyama SS.**

Risk factors and impact of allergic bronchopulmonary aspergillosis in *Pseudomonas aeruginosa*-negative CF patients  
*Pediatric Allergy and Immunology* 2018; 29: 726 - 731

- Dennis EA., Coats MT., Griffin S., Pang B., Briles DE., Crain MJ., Swords WE.**  
Hyperencapsulated mucoid pneumococcal isolates from patients with cystic fibrosis have increased biofilm density and persistence in vivo  
*Pathogens and Disease* 2018; 76: 7:fty073
- Dobay O., Laub K., Stercz B., Keri A., Balazs B., Tothpal A., Kardos S., Jaikumpun P., Ruksakiet K., Quinton PM., Zsembery A.**  
Bicarbonate Inhibits Bacterial Growth and Biofilm Formation of Prevalent Cystic Fibrosis Pathogens  
*Frontiers in Microbiology* 2018; 9: ArNo: 2245
- Dupont C., Jumas-Bilak E., Doisy C., Aujoulat F., Chiron R., Marchandin H.**  
Chronic Airway Colonization by *Achromobacter xylosoxidans* in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment  
*Applied and Environmental Microbiology* 2018; 84: 23:UNSP e01739
- Eckstrom K., Willsey GG., LiPuma JJ., Wargo MJ.**  
Draft Genome Sequences of Two Cystic Fibrosis Strains of *Stenotrophomonas maltophilia*, AU30115 and AU32848  
*Microbiology Resource Announcements* 2018; 7: 11:UNSP e01137
- Eyns H., Pierard D., De Wachter E., Eeckhout L., Vaes P., Malfroot A.**  
Respiratory Bacterial Culture Sampling in Expectorating and Non-expectorating Patients With Cystic Fibrosis  
*Frontiers in Pediatrics* 2018; 6: ArNo: 403
- Faure E., Kwong K., Nguyen D.**  
*Pseudomonas aeruginosa* in Chronic Lung Infections: How to Adapt Within the Host?  
*Frontiers in Immunology* 2018; 9: ArNo: 2416
- Gomes MC., Tasrini Y., Subramoni S., Agnoli K., Feliciano JR., Eberl L., Sokol P., O'Callaghan D., Vergunst AC.**  
The *afc* antifungal activity cluster, which is under tight regulatory control of *ShvR*, is essential for transition from intracellular persistence of *Burkholderia cenocepacia* to acute pro-inflammatory infection  
*PLoS Pathogens* 2018; 14: 12:e1007473
- Gramegna A., Millar BC., Blasi F., Elborn JS., Downey DG., Moore JE.**  
In vitro antimicrobial activity of ceftolozane/tazobactam against *Pseudomonas aeruginosa* and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis  
*Journal of Global Antimicrobial Resistance* 2018; 14: 224 - 227
- Green H., Jones AM.**  
Emerging Gram-negative bacteria: pathogenic or innocent bystanders  
*Current Opinion in Pulmonary Medicine* 2018; 24: 592 - 598
- Gungor O., Sampaio-Maia B., Amorim A., Araujo R., Erturan Z.**  
Determination of Azole Resistance and TR34/L98H Mutations in Isolates of *Aspergillus* Section *Fumigati* from Turkish Cystic Fibrosis Patients  
*Mycopathologia* 2018; 183: 913 - 920
- Hahn A., Burrell A., Fanous H., Chaney H., Sami I., Perez GF., Koumbourlis AC., Freishtat RJ., Crandall KA.**  
Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity  
*Heliyon* 2018; 4: 9:UNSP e00795
- Heriot M., Nottelet B., Garric X., D'Este M., Richards GR., Moriarty FT., Eglin D., Guillaume O.**  
Interaction of gentamicin sulfate with alginate and consequences on the physico-chemical properties of alginate-containing biofilms  
*International Journal of Biological Macromolecules* 2019; 121: 390 - 397
- Hong G., Psoter KJ., Jennings MT., Merlo CA., Boyle MP., Hadjiliadis D., Kawut SM., Lechtzin N.**  
Risk factors for persistent *Aspergillus* respiratory isolation in cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 624 - 630
- Hoo ZH., Coates E., Maguire C., Cantrill H., Shafi N., Nash EF., McGowan A., Bourke SJ., Flight WG., Daniels TV., Nightingale JA., Allenby MI., Curley R., Wildman MJ.**  
Pragmatic criteria to define chronic *Pseudomonas aeruginosa* infection among adults with cystic fibrosis  
*European Journal of Clinical Microbiology & Infectious Diseases* 2018; 37: 2219 - 2222
- Horikawa T., Hung LW., Kim HB., Shaya D., Kim CY., Terwilliger TC., Yamashita E., Aoki M., Okada U., Murakami S.**  
*BpeB*, a major resistance-nodulation-cell division transporter from *Burkholderia cenocepacia*: construct design, crystallization and preliminary structural analysis  
*Acta Crystallographica Section F-structural Biology Communications* 2018; 74: 710 - 716
- Hoyle N., Zhvaniya P., Balarjishvili N., Bolkvadze D., Nadareishvili L., Nizharadze D., Wittmann J., Rohde C., Kutateladze M.**  
Phage therapy against *Achromobacter xylosoxidans* lung infection in a patient with cystic fibrosis: a case report  
*Research in Microbiology* 2018; 169: 540 - 542
- Huang Q., Wang YQ., Xia Y., Li LW., Luo J., Xia SX., Sun Y., Miao YL., Wang KH., Chen Y.**  
Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients  
*Medicine* 2018; 97: 37:e12248
- Hurley MN., Smyth AR.**  
*Staphylococcus aureus* in cystic fibrosis: pivotal role or bit part actor?  
*Current Opinion in Pulmonary Medicine* 2018; 24: 586 - 591
- Jonckheere L., Schelstraete P., Van Simaey L., Van Braeckel E., Willekens J., Van Daele S., De Baets F., Vaneechoutte M.**  
Establishing the diagnosis of chronic colonization with *Pseudomonas aeruginosa* of cystic fibrosis patients: Comparison of the European consensus criteria with genotyping of *P. aeruginosa* isolates  
*Journal of Cystic Fibrosis* 2018; 17: 729 - 735
- Kevat A., Carzino R., Massie J., Harrison J., Griffiths AL.**  
Elimination of Australian epidemic strain (AES1) *Pseudomonas aeruginosa* in a pediatric cystic fibrosis center  
*Pediatric Pulmonology* 2018; 53: 1498 - 1503
- Kiedrowski MR., Bomberger JM.**  
Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract  
*Frontiers in Immunology* 2018; 9: ArNo: 3067
- Kirienko DR., Kang D., Kirienko NV.**  
Novel Pyoverdine Inhibitors Mitigate *Pseudomonas aeruginosa* Pathogenesis  
*Frontiers in Microbiology* 2019; 9: ArNo: 3317
- Kumar SS., Tandberg JL., Penesyan A., Elbourne LDH., Suarez-Bosche N., Don E., Skadberg E., Fenaroli F., Cole N., Winther-Larsen HC., Paulsen IT.**  
Dual Transcriptomics of Host-Pathogen Interaction of Cystic Fibrosis Isolate *Pseudomonas aeruginosa* PASS1 With Zebra fish  
*Frontiers in Cellular and Infection Microbiology* 2018; 8: ArNo: 406
- Lee AC., Jones AL.**  
Multi-resistant *Pseudomonas aeruginosa* ST235 in cystic fibrosis  
*Paediatric Respiratory Reviews* 2018; 27: 18 - 20
- Lee CW., Wu CH., Chiang YC., Chen YL., Chang KT., Chuang CC., Lee IT.**  
Carbon monoxide releasing molecule-2 attenuates *Pseudomonas aeruginosa*-induced ROS-dependent ICAM-1 expression in human pulmonary alveolar epithelial cells  
*Redox Biology* 2018; 18: 93 - 103
- Lim SZP., Fitzgerald DA.**  
Treating resistant *Pseudomonas aeruginosa* lung disease in young children with cystic fibrosis  
*Paediatric Respiratory Reviews* 2018; 27: 33 - 36
- Liu TH., Zhang YZ., Wan QQ.**  
*Pseudomonas aeruginosa* bacteremia among liver transplant recipients  
*Infection and Drug Resistance* 2018; 11: 2345 - 2356



- Lotfy WA., Atalla RG., Sabra WA., El-Helow ER.**  
Expression of extracellular polysaccharides and proteins by clinical isolates of *Pseudomonas aeruginosa* in response to environmental conditions  
*International Microbiology* 2018; 21: 129 - 142
- Lozano C., Azcona-Gutierrez JM., Van Bambeke F., Saenz Y.**  
Great phenotypic and genetic variation among successive chronic *Pseudomonas aeruginosa* from a cystic fibrosis patient  
*PLoS One* 2018; 13: 9:e0204167
- Mangiaterra G., Amiri M., Di Cesare A., Pasquaroli S., Manso E., Cirilli N., Citterio B., Vignaroli C., Biavasco F.**  
Detection of viable but non-culturable *Pseudomonas aeruginosa* in cystic fibrosis by qPCR: a validation study  
*BMC Infectious Diseases* 2018; 18: ArNo: 701
- Martin LW., Robson CL., Watts AM., Gray AR., Wainwright CE., Bell SC., Ramsay KA., Kidd TJ., Reid DW., Brockway B., Lamont IL.**  
Expression of *Pseudomonas aeruginosa* Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients  
*Antimicrobial Agents and Chemotherapy* 2018; 62: 11:e01789-18
- Martiniano SL., Nick JA., Daley CL.**  
Nontuberculous Mycobacterial Infections in Cystic Fibrosis  
*Thoracic Surgery Clinics* 2019; 29: 95 -
- Moola F.**  
The complexities of contagion: The experience of social isolation among children and youth living with cystic fibrosis in Canada  
*Journal of Child Health Care* 2018; 22: 631 - 645
- Neubauer C., Kasi AS., Grahl N., Sessions AL., Kopf SH., Kato R., Hogan DA., Newman DK.**  
Refining the Application of Microbial Lipids as Tracers of *Staphylococcus aureus* Growth Rates in Cystic Fibrosis Sputum  
*Journal of Bacteriology* 2018; 200: 24:e00365
- Ortega MM., Gallego MEQ., Hernandez LC., Borrego EP., Pecellin ID.**  
*Mycobacterium Lentiflavum* in Cystic Fibrosis Subjects. A Colonizer or a True Pathogen?  
*Archivos de Bronconeumologia* 2018; 54: 639 - 640
- Parkins MD., Somayaji R., Waters VJ., Richter AM., Fazli M., Schmid N., Shilling R., Suppiger A., Givskov M., Eberl L., Tolker-Nielsen T.**  
Key Players and Individualists of Cyclic-di-GMP Signaling in *Burkholderia cenocepacia*  
*Frontiers in Microbiology* 2019; 9: ArNo: 3286
- Perault AL., Cotter PA.**  
Three Distinct Contact-Dependent Growth Inhibition Systems Mediate Interbacterial Competition by the Cystic Fibrosis Pathogen *Burkholderia dolosa*  
*Journal of Bacteriology* 2018; 200: 22:e00428-18
- Pita T., Feliciano JR., Leitao JH.**  
Small Noncoding Regulatory RNAs from *Pseudomonas aeruginosa* and *Burkholderia cepacia* Complex  
*International Journal of Molecular Sciences* 2018; 19: 12:3759
- Pollini S., Di Pilato V., Landini G., Di Maggio T., Cannatelli A., Sottotetti S., Cariani L., Aliberti S., Blasi F., Sergio F., Rossolini GM., Pallecchi L.**  
In vitro activity of N-acetylcysteine against *Stenotrophomonas maltophilia* and *Burkholderia cepacia* complex grown in planktonic phase and biofilm  
*PLoS One* 2018; 13: 10:e0203941
- Pompilio A., Geminiani C., Mantini P., Siriwardena TN., Di Bonaventura I., Reymond JL., Di Bonaventura G.**  
Peptide dendrimers as "lead compounds" for the treatment of chronic lung infections by *Pseudomonas aeruginosa* in cystic fibrosis patients: in vitro and in vivo studies  
*Infection and Drug Resistance* 2018; 11: 1767 - 1782
- Poudyal B., Sauer K.**  
The PA3177 Gene Encodes an Active Diguanylate Cyclase That Contributes to Biofilm Antimicrobial Tolerance but Not Biofilm Formation by *Pseudomonas aeruginosa*  
*Antimicrobial Agents and Chemotherapy* 2018; 62: 10:e01049-18
- Powell LC., Pritchard MF., Ferguson EL., Powell KA., Patel SU., Rye PD., Sakellakou SM., Buurma NJ., Brilliant CD., Copping JM., Menzies GE., Lewis PD., Hill KE., Thomas DW.**  
Targeted disruption of the extracellular polymeric network of *Pseudomonas aeruginosa* biofilms by alginate oligosaccharides  
*NPJ Biofilms and Microbiomes* 2018; 4: ArNo: UNSP 13
- Ravnholt C., Kolpen M., Skov M., Moser C., Katzenstein TL., Pressler T., Hoiby N., Qvist T.**  
The importance of early diagnosis of *Mycobacterium abscessus* complex in patients with cystic fibrosis  
*APMIS* 2018; 126: 885 - 891
- Redero M., Lopez-Causape C., Aznar J., Oliver A., Blazquez J., Prieto AI.**  
Susceptibility to R-pyocins of *Pseudomonas aeruginosa* clinical isolates from cystic fibrosis patients  
*Journal of Antimicrobial Chemotherapy* 2018; 73: 2770 - 2776
- Rouard C., Garnier F., Leraut J., Lepointeur M., Rahajamananav L., Languepin J., Ploy MC., Bourgeois-Nicolaos N., Doucet-Populaire F.**  
Emergence and Within-Host Genetic Evolution of Methicillin-Resistant *Staphylococcus aureus* Resistant to Linezolid in a Cystic Fibrosis Patient  
*Antimicrobial Agents and Chemotherapy* 2018; 62: 12:e00720-18
- Schick A., Kassen R.**  
Rapid diversification of *Pseudomonas aeruginosa* in cystic fibrosis lung-like conditions  
*Proceedings of the National Academy of Sciences of the United States* 2018; 115: 10714 - 10719
- Schwerdt M., Neumann C., Schwartbeck B., Kampmeier S., Herzog S., Gorlich D., Dubbers A., Grosse-Onnebrink J., Kessler C., Kuster P., Schultingkemper H., Treffon J., Peters G., Kahl BC.**  
*Staphylococcus aureus* in the airways of cystic fibrosis patients - A retrospective long-term study  
*International Journal of Medical Microbiology* 2018; 308: 631 - 639
- Secor PR., Michaels LA., Ratjen A., Jennings LK., Singh PK.**  
Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in *Pseudomonas aeruginosa*  
*Proceedings of the National Academy of Sciences of the United States* 2018; 115: 10780 - 10785
- Song Y., Keatley LR., Middleton PG.**  
Methicillin-resistant *Staphylococcus aureus* in health-care workers with cystic fibrosis in Sydney  
*Respirology Case Reports* 2018; 6: 9:UNSP e00378
- Stockwell RE., Wood ME., He C., Sherrard LJ., Ballard EL., Kidd TJ., Johnson GR., Knibbs LD., Morawska L., Bell SC.**  
Face Masks Reduce the Release of *Pseudomonas aeruginosa* Cough Aerosols When Worn for Clinically Relevant Periods  
*American Journal of Respiratory and Critical Care Medicine* 2018; 198: 1339 - 1342
- Subedi D., Vijay AK., Kohli GS., Rice SA., Willcox M.**  
Association between possession of ExoU and antibiotic resistance in *Pseudomonas aeruginosa*  
*PLoS One* 2018; 13: 9:e0204936
- Tetz G., Tetz V.**  
Draft Genome Sequence of *Chryseobacterium mucoviscidosis* sp. nov. Strain VT16-26, Isolated from the Bronchoalveolar Lavage Fluid of a Patient with Cystic Fibrosis  
*Microbiology Resource Announcements* 2018; 6: 2:UNSP e01473-
- Tracy MC., Moss RB.**  
The myriad challenges of respiratory fungal infection in cystic fibrosis  
*Pediatric Pulmonology* 2018; 53:
- Trend S., Chang BJ., O'Dea M., Stick SM., Kicic A.**  
Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis  
*Frontiers in Pharmacology* 2018; 9: ArNo: 1330

**van der Bruggen T., Kolecka A., Theelen B., Kwakkel-van Erp JM., Arets B., Boekhout T.**

Cutaneotrichosporon (Cryptococcus) cyanovorans, a basidiomycetous yeast, isolated from the airways of cystic fibrosis patients  
*Medical Mycology Case Reports* 2018; 22: 18 - 20

**Vernocchi P., Del Chierico F., Russo A., Majo F., Rossitto M., Valerio M., Casadei L., La Stora A., De Filippis F., Rizzo C., Manetti C., Paci P., Ercolini D., Marini F., Fiscarelli EV., Dallapiccola B., Lucidi V., Miccheli A., et al**  
Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype  
*PLoS One* 2018; 13: 12:e0208171

**Vinokurova LV., Baimakanova GE., Krasovsky SA., Silvestrova SY., Dubtsova EA., Varvanina GG., Bordin DS.**  
Functional insufficiency of the pancreas and the metabolic activity of the microbiota in cystic fibrosis adults patients  
*Terapevticheskii Arkhiv* 2018; 90: 84 - 88

**Vongthilath R., Thiriez BR., Dehillotte C., Lemonnier L., Guillien A., Degano B., Dalphin ML., Dalphin JC., Plesiat P.**  
Clinical and microbiological characteristics of cystic fibrosis adults never colonized by *Pseudomonas aeruginosa*: Analysis of the French CF registry  
*PLoS One* 2019; 14: 1:e0210201

**Wang J., Li Y., Yan HZ., Luo XH., Feng XQ., Lu LF., Wang WJ.**  
Association between the *Pseudomonas aeruginosa* type III secretion system, antibiotic resistance and clinical features  
*International Journal of Clinical and Experimental Medicine* 2018; 11: 11120 - 11126

**Wood ME., Stockwell RE., Johnson GR., Ramsay KA., Sherrard LJ., Kidd TJ., Cheney J., Ballard EL., O'Rourke P., Jabbour N., Wainwright CE., Knibbs LD., Sly PD., Morawska L., Bell SC.**  
Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei  
*Thorax* 2019; 74: 87 - 90

**Woods PW., Haynes ZM., Mina EG., Marques CNH.**  
Maintenance of *S. aureus* in Co-culture With *P. aeruginosa* While Growing as Biofilms  
*Frontiers in Microbiology* 2019; 9: ArNo: 3291  
aeruginosa Infections in Cystic Fibrosis  
*Clinical Microbiology Reviews* 2018; 31: 4:UNSP e00019-

**Yu ZJ., Deslouches B., Walton WG., Redinbo MR., Di YP.**  
Enhanced biofilm prevention activity of a SPLUNC1-derived antimicrobial peptide against *Staphylococcus aureus*  
*PLoS One* 2018; 13: 9:e0203621

**Zhao JM., Cheng W., He XG., Liu YL.**  
The co-colonization prevalence of *Pseudomonas aeruginosa* and *Aspergillus fumigatus* in cystic fibrosis: A systematic review and meta-analysis  
*Microbial Pathogenesis* 2018; 125: 122 - 128

**Zhao JM., Yu WC.**  
Interaction between *Pseudomonas aeruginosa* and *Aspergillus fumigatus* in cystic fibrosis  
*PeerJ* 2018; 6: ArNo: e5931

**Zhao TH., Zhang YH., Wu HJ., Wang D., Chen YH., Zhu MJ., Ma LZ.**  
Extracellular aminopeptidase modulates biofilm development of *Pseudomonas aeruginosa* by affecting matrix exopolysaccharide and bacterial cell death  
*Environmental Microbiology Reports* 2018; 10: 583 - 593

## Nutrition

**Abu-El-Hajja M., Uc A., Werlin SL., Freeman AJ., Georgieva M., Jojkic-Pavkov D., Kalnins D., Kochavi B., Koot BGP., Van Biervliet S., Walkowiak J., Wilschanski M., Morinville VD.**  
Nutritional Considerations in Pediatric Pancreatitis: A Position Paper from the NASPHAN Pancreas Committee and ESPHAN Cystic Fibrosis/Pancreas Working Group  
*Journal of Pediatric Gastroenterology and Nutrition* 2018; 67: 131 - 143

**de Vries JJV., Chang AB., Bonifant CM., Shevill E., Marchant JM.**

Vitamin A and beta (beta)-carotene supplementation for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 8:CD006751

**Grzelak T., Mikolajczyk K.**  
Pleiotropic effect of vitamin D in cystic fibrosis  
*Advances in Respiratory Medicine* 2018; 86: 192 - 196

**Lopez-Mejia L., Vergara-Vazquez M., Lopez-Olivan F., Bautista-Silva M., Guillen-Lopez S.**  
Nutritional management in patients with cystic fibrosis  
*Acta Pediatrica de Mexico* 2018; 39:

**Pastor O., Guzman-Lafuente P., Serna J., Munoz-Hernandez M., Neyra AL., Garcia-Rozas P., Garcia-Seisededos D., Alcazar A., Lasuncion MA., Busto R., Ferreiro AL.**  
A comprehensive evaluation of omega-3 fatty acid supplementation in cystic fibrosis patients using lipidomics  
*Journal of Nutritional Biochemistry* 2019; 63: 197 - 205

**Rozga M., Handu D.**  
Nutrition Care for Patients with Cystic Fibrosis: An Evidence Analysis Center Scoping Review  
*Journal of the Academy of Nutrition and Dietetics* 2019; 119: 137 - +

**Sapiejka E., Krzyzanowska-Jankowska P., Wenska-Chyzy E., Szczepanik M., Walkowiak D., Cofta S., Pogorzelski A., Skorupa W., Walkowiak J.**  
Vitamin E status and its determinants in patients with cystic fibrosis  
*Advances in Medical Sciences* 2018; 63: 341 - 346

**Schechter MS., Michel S., Liu SF., Seo BW., Kapoor M., Khurmi R., Haupt M.**  
Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis  
*Journal of Pediatric Gastroenterology and Nutrition* 2018; 67: 520 - 526

**Sutherland R., Katz T., Liu V., Quintano J., Brunner R., Tong CW., Collins CE., Ooi CY.**  
Dietary intake of energy-dense, nutrient-poor and nutrient-dense food sources in children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 804 - 810

**Thursfield RM., Naderi K., Leaver N., Rosenthal M., Alton EFWF., Bush A., Davies JC.**  
Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency  
*Journal of Cystic Fibrosis* 2018; 17: 657 - 665

## Physiotherapy

**Ghasempour M., Bilan N., Rezazadehsaatlou M.**  
Positive Expiratory Pressure (PEP) versus Conventional Chest Physiotherapy in Pediatric Patients with Acute Exacerbation of Cystic Fibrosis  
*International Journal of Pediatrics-Mashhad* 2019; 7: 8881 - 8888

**Wheatley CM., Baker SE., Daines CM., Phan H., Martinez MG., Morgan WJ., Snyder EM.**  
Influence of the Vibrating Percussion on pulmonary function and sputum expectoration in individuals with cystic fibrosis  
*Therapeutic Advances in Respiratory Disease* 2018; 12: ArNo: 17534666

## Psychosocial

**Bell SC., Armstrong D., Harrington G., Jardine L., Divakaran R., Loff B., Middleton PG., McDonald T., Rowland K., Wishart M., Wood ME., Stuart RL.**  
Work environment risks for health care workers with cystic fibrosis  
*Respirology* 2018; 23: 1190 - 1197

**Bhat JI., Wani WA., Charoo BA., Ali SW., Ahmad QL., Ahangar AA.**

Prevalence of Depression among Caregivers of Indian Children with Cystic Fibrosis

*Indian Journal of Pediatrics* 2018; 85: 974 - 977

**Brown PS., Durham D., Tivis RD., Stamper S., Waldren C., Toews SE., Gordon B., Robb TA.**

Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis: Community Case Study

*Frontiers in Public Health* 2018; 6: ArNo: 348

**Burnet E., Hubert D., Champreux J., Honore I., Kanaan R., Panzo R., Burgel PR.**

A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre

*Journal of Cystic Fibrosis* 2018; 17: 636 - 642

**Clarke AJ., Wallgren-Pettersson C.**

Ethics in genetic counselling

*Journal of Community Genetics* 2019; 10: 3 - 33

**Colombo C., Catastini P., Brivio A., Acone B., Dang P., Quattrucci S.**

Delphi poll to assess consensus on issues influencing long-term adherence to treatments in cystic fibrosis among Italian health care professionals

*Patient Preference and Adherence* 2018; 12: 2233 - 2241

**Gancz DW., Cunha MT., Leone C., Rodrigues JC., Adde FV.**

Quality of life amongst adolescents and young adults with cystic fibrosis: correlations with clinical outcomes

*Clinics* 2018; 73: ArNo: UNSP e42

**Gomes A., Rothpletz-Puglia P., Matarese L., Ziegler J.**

The Impact of Weight Status on Health-Related Quality of Life and Body Image in Adults With Cystic Fibrosis A Narrative Review

*Topics in Clinical Nutrition* 2018; 33: 164 - 178

**Grosse SD., Do TQN., Vu M., Feng LB., Berry JG., Sawicki GS.**  
Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016

*Pediatric Pulmonology* 2018; 53: 1611 - 1618

**Iscar-Urrutia M., Madrid-Carbajal CJ., Rubinos-Cuadrado G., Fernandez-Alvarez R., Vazquez-Lopez MJ., Hernandez-Gonzalez C., Enriquez-Rodriguez AL., Garcia-Clemente M.**

Objective and Subjective Sleep Efficiency in Adult Patients with Cystic Fibrosis and Impact on Quality of Life

*Lung* 2018; 196: 761 - 767

**Lapp V., Chase SK.**

How Do Youth with Cystic Fibrosis Perceive Their Readiness to Transition to Adult Healthcare Compared to Their Caregivers' Views?

*Journal of Pediatric Nursing-nursing Care of Children & Families* 2018; 43: 104 - 110

**Linnemann RW., Friedman D., Altstein LL., Islam S., Bach KT., Georgiopoulos AM., Moskowitz SM., Yonker LM.**

Advance Care Planning Experiences and Preferences among People with Cystic Fibrosis

*Journal of Palliative Medicine* 2018; 28: 3177 - 3181

**Louie JM., Hong LT., Garavaglia LR., Pinal DI., O'Brien CE.**

Evaluation of Home Medication Reconciliation by Clinical Pharmacists for Adult and Pediatric Cystic Fibrosis Patients

*Pharmacy* 2018; 6: 3:91

**Muther EF., Polineni D., Sawicki GS.**

Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience

*Pediatric Pulmonology* 2018; 53:

**Norris E., Phillips S., Butler C., James K.**

Sex and Relationships Education for Individuals with Cystic Fibrosis: A Service-Based Approach

*Sexuality and Disability* 2018; 36: 363 - 376

**Oud L., Chan YM.**

Predictors and variation of routine home discharge in critically ill adults with cystic fibrosis

*Heart & Lung* 2018; 47: 511 - 515

**Shelley J., Fairclough SJ., Knowles ZR., Southern KW., McCormack P., Dawson EA., Graves LEF., Hanlon C.**

A formative study exploring perceptions of physical activity and physical activity monitoring among children and young people with cystic fibrosis and health care professionals

*BMC Pediatrics* 2018; 18: ArNo: 335

**Sole A., Oliveira C., Perez I., Hervas D., Valentine V., Yopez ANB., Oliveira G., Quittner AL.**

Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen/Adult) New tool for monitoring psychosocial health in CF

*Journal of Cystic Fibrosis* 2018; 17: 672 - 679

**Spitzer N., Legare TB., Patel P., Toselli N., Livingston F.**

The Prevalence and Effect of Comorbid Cystic Fibrosis and Attention Deficit Hyperactivity Disorders on Hospitalizations: A Retrospective Analysis

*Cureus* 2018; 10: 7:UNSP e3048

**Vandeleur M., Walter LM., Armstrong DS., Robinson P., Nixon GM., Horne RSC.**

Quality of life and mood in children with cystic fibrosis: Associations with sleep quality

*Journal of Cystic Fibrosis* 2018; 17: 811 - 820

**Verkleij M., de Winter D., Hurley MA., Abbott J.**

Implementing the International Committee on Mental Health in Cystic Fibrosis (ICMH) guidelines: Screening accuracy and referral-treatment pathways

*Journal of Cystic Fibrosis* 2018; 17: 821 - 827

**Wojtaszczyk A., Glajchen M., Portenoy RK., Berdella M., Walker P., Barrett M., Chen J., Plachta A., Balzano J., Fresenius A., Wilder K., Langfelder-Schwind E., Dhingra L.**

Trajectories of caregiver burden in families of adult cystic fibrosis patients

*Palliative & Supportive Care* 2018; 16: 732 - 740

## Pulmonology

**Al Momani H., Perry A., Jones R., McDonnell M., Krishnan A., Robertson A., Griffin M., Rutherford R., Brodlie M., Pearson J., Bourke S., Ward C.**

Risk factors for lung disease progression in children with cystic fibrosis

*European Respiratory Journal* 2018; 52: 4:1801492

**Brugha R., Edmondson C., Davies JC.**

Outdoor air pollution and cystic fibrosis

*Paediatric Respiratory Reviews* 2018; 28: 80 - 86

**Buras M., Simoncini A., Gungor A.**

Auto-obliteration of maxillary sinuses through osteoneogenesis in children with cystic fibrosis: A possible new way to reduce morbidity

*American Journal of Otolaryngology* 2018; 39: 737 - 740

**Button B., Goodell HP., Atieh E., Chen YC., Williams R., Shenoy S., Lackey E., Shenkute NT., Cai LH., Dennis RG., Boucher RC., Rubinstein M.**

Roles of mucus adhesion and cohesion in cough clearance

*Proceedings of the National Academy of Sciences of the United States* 2018; 115: 12501 - 12506

**Chandler JD., Horati H., Walker DI., Pagliano E., Tirouvanziam R., Veltman M., Scholte BJ., Janssens HM., Go YM., Jones DP.**

Determination of thiocyanate in exhaled breath condensate

*Free Radical Biology and Medicine* 2018; 126: 334 - 340

**Clarke D., Gorman I., Ringholz F., McDermott M., Cox DW., Greally P., Linnane B., Mc Nally P.**

Pulmonary aspiration in preschool children with cystic fibrosis

*Respiratory Research* 2018; 19: ArNo: 255

**Eiserich JP., Ott SP., Kadir T., Morrissey BM., Hayakawa KA., La Merrill MA., Cross CE.**

Quantitative assessment of cyanide in cystic fibrosis sputum and its oxidative catabolism by hypochlorous acid

*Free Radical Biology and Medicine* 2018; 129: 146 - 154

**Ermund A., Meiss LN., Dolan B., Bahr A., Klymiuk N., Hansson GC.**

The mucus bundles responsible for airway cleaning are retained in cystic fibrosis and by cholinergic stimulation  
*European Respiratory Journal* 2018; 52: 2:1800457

**Forno E., Abraham N., Winger DG., Rosas-Salazar C., Kurland G., Weiner DJ.**

Perception of Pulmonary Function in Children with Asthma and Cystic Fibrosis  
*Pediatric Allergy Immunology and Pulmonology* 2018; 31: 139 - 145

**Gallant JN., Mitchell MB., Virgin FW.**

Update on sinus disease in children with cystic fibrosis: advances in treatment modalities, microbiology, and health-related quality-of-life instruments  
*Current Opinion in Otolaryngology & Head and Neck Surgery* 2018; 26: 417 - 420

**Hill DB., Long RF., Kissner WJ., Atieh E., Garbarine IC., Markovetz MR., Fontana NC., Christy M., Habibpour M., Tarran R., Forest MG., Boucher RC., Button B.**

Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH  
*European Respiratory Journal* 2018; 52: 6:1801297

**Lafoeste H., Regard L., Martin C., Chassagnon G., Burgel PR.**

Acute pulmonary and non-pulmonary complications in adults with cystic fibrosis  
*Revue de Pneumologie Clinique* 2018; 74: 267 - 278

**Magalhaes M., Tost J., Pineau F., Rivals I., Busato F., Alary N., Mely L., Leroy S., Murriss M., Caimmi D., Claustres M., Chiron R., De Sario A.**

Dynamic changes of DNA methylation and lung disease in cystic fibrosis: lessons from a monogenic disease  
*Epigenomics* 2018; 10: 1131 - 1145

**Massip-Copiz MM., Santa-Coloma TA.**

Extracellular pH and lung infections in cystic fibrosis  
*European Journal of Cell Biology* 2018; 97: 402 - 410

**Mendelsohn L., Wijers C., Gupta R., Marozkina N., Li C., Gaston B.**

A novel, noninvasive assay shows that distal airway oxygen tension is low in cystic fibrosis, but not in primary ciliary dyskinesia  
*Pediatric Pulmonology* 2019; 54: 27 - 32

**Nolt VD., Pijut KD., Autry EB., Williams WC., Burgess DS., Burgess DR., Arora V., Kuhn RJ.**

Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation  
*Pediatric Pulmonology* 2019; 54: 33 - 39

**Perrem L., Rayment JH., Ratjen F.**

The lung clearance index as a monitoring tool in cystic fibrosis: ready for the clinic?  
*Current Opinion in Pulmonary Medicine* 2018; 24: 579 - 585

**Radine A., Werner C., Raidt J., Dougherty GW., Kerschke L., Omran H., Grosse-Onnebrink J.**

Comparison of Nocturnal Cough Analysis in Healthy Subjects and in Patients with Cystic Fibrosis and Primary Ciliary Dyskinesia: A Prospective Observational Study  
*Respiration* 2019; 97: 60 - 69

**Regard L., Martin C., Chassagnon G., Burgel PR.**

Acute and chronic non-pulmonary complications in adults with cystic fibrosis  
*Expert Review of Respiratory Medicine* 2019; 13: 23 - 38

**Roethlisberger K., Nyilas S., Riedel T., Wolfensberger J., Singer F., Latzin P.**

Short-Term Effects of Elastic Chest Wall Restriction on Pulmonary Function in Children with Cystic Fibrosis  
*Respiration* 2018; 96: 535 - 542

**Schechter MS., Schmidt HJ., Williams R., Norton R., Taylor D., Molzhon A.**

Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 769 - 778

**Szentpetery S., Flume PA.**

Optimizing outcomes of pulmonary exacerbations in cystic fibrosis  
*Current Opinion in Pulmonary Medicine* 2018; 24: 606 - 611

**Tomlinson OW., Barker AR., Chubbock LV., Stevens D., Saynor ZL., Oades PJ., Williams CA.**

Analysis of oxygen uptake efficiency parameters in young people with cystic fibrosis  
*European Journal of Applied Physiology* 2018; 118: 2055 - 2063

**Vendrusculo FM., Heinzmann JP., da Silva JS., Ruiz MP., Donadio MVF.**

Peak Oxygen Uptake and Mortality in Cystic Fibrosis: Systematic Review and Meta-Analysis  
*Respiratory Care* 2019; 64: 91 - 98

**Webster MJ., Reidel B., Tan CD., Ghosh A., Alexis NE., Donaldson SH., Kesimer M., Ribeiro CMP., Tarran R.**

SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration  
*European Respiratory Journal* 2018; 52: 4:1800668

[Anonymous].

Reevaluating approaches to cystic fibrosis pulmonary exacerbations  
*Pediatric Pulmonology* 2018; 53:

[Anonymous].

Retraction: Phenazine Content in the Cystic Fibrosis Respiratory Tract Negatively Correlates with Lung Function and Microbial Complexity  
*American Journal of Respiratory Cell and Molecular Biology* 2019; 60: 134

## Radiology

**Chassagnon G., Martin C., Burgel PR., Hubert D., Fajac I., Paragios N., Zacharaki EL., Legmann P., Coste J., Revel MP.**

An automated computed tomography score for the cystic fibrosis lung  
*European Radiology* 2018; 28: 5111 - 5120

**Hill DB., Long RF., Kissner WJ., Atieh E., Garbarine IC., Markovetz MR., Fontana NC., Christy M., Habibpour M., Tarran R., Forest MG., Boucher RC., Button B.**

Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH  
*European Respiratory Journal* 2018; 52: 6:1801297

**Manzini M., Schweiger C., Manica D., Machado LR., Lopes PDD., Sekine L., Faccin CS., BejzmanPitche O., CauduroMarostica PJ.**

Sinonasal computed tomography in pediatric cystic fibrosis: do we know the indications?  
*International Journal of Pediatric Otorhinolaryngology* 2018; 113: 204 - 207

**Nandurkar R., Lau KK.**

Ultra-low-dose Computed Tomography in Management of Pulmonary Abscess Caused by Cystic Fibrosis  
*Hong Kong Journal of Radiology* 2018; 21: 271 - 273

**Naseri Z., Sherafat S., Moghaddam HA., Modaresi M., Pak N., Zamani F.**

Semi-automatic Methods for Airway and Adjacent Vessel Measurement in Bronchiectasis Patterns in Lung HRCT Images of Cystic Fibrosis Patients  
*Journal of Digital Imaging* 2018; 31: 727 - 737

**Newbegin K., Pilkington K., Shanthikumar S., Ranganathan S.**

Clinical utility of surveillance computed tomography scans in infants with cystic fibrosis  
*Pediatric Pulmonology* 2018; 53: 1387 - 1390

**Poetter-Lang S., Stauffer K., Baltzer P., Tamand D., Muin D., Bastati N., Halilbasic E., Hodge JC., Trauner M., Kazemi-Shirazi L., Ba-Salamah A.**

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study  
*European Radiology* 2019; 29: 1048 - 1058

**Sanders DB., Li ZH., Parker-McGill K., Farrell P., Brody AS.**  
Quantitative chest computerized tomography and FEV1 equally identify pulmonary exacerbation risk in children with cystic fibrosis  
*Pediatric Pulmonology* 2018; 53: 1369 - 1377

**Smith LJ., Collier GJ., Marshall H., Hughes PJC., Biancardi AM., Wildman M., Aldag I., West N., Horsley A., Wild JM.**  
Patterns of regional lung physiology in cystic fibrosis using ventilation magnetic resonance imaging and multiple-breath washout  
*European Respiratory Journal* 2018; 52: 5:1800821

**Zha W., Nagle SK., Cadman RV., Schiebler ML., Fain SB.**  
Three-dimensional Isotropic Functional Imaging of Cystic Fibrosis Using Oxygen-enhanced MRI: Comparison with Hyperpolarized He-3 MRI  
*Radiology* 2019; 290: 229 - 237

## Screening

**Castellani C., Boner AL.**  
Aquagenic wrinkling and cystic fibrosis carriership: A dubious relationship  
*European Journal of Internal Medicine* 2018; 57: E43

**David J., Chrastina P., Vinohradská H., Al Taji E., Holubova A., Hlídková E., Kozich V., Votava F.**  
Neonatal screening in the Czech Republic: increased prevalence of selected diseases in low birthweight neonates  
*European Journal of Pediatrics* 2018; 177: 1697 - 1704

**Ibarra-Gonzalez I., Gutierrez-Morales G., Vela-Amieva M., Castillo-Mogel JA., Herrera-Perez LD., Caamal-Parra G., Herrera-Maldonado N., Garcia-Flores EP.**  
Challenges and opportunities in the implementation of the neonatal screening for cystic fibrosis  
*Acta Pediatrica de Mexico* 2018; 39:

**Martinez EMC., Gonzalez EC., Tejada Y., Frometa A., Martin O., Espinosa M., del Rio L., Perez PL., Morejon G., Perea Y., Melchor A.**  
An Enzyme Immunoassay for Determining Immunoreactive Trypsinogen (IRT) in Dried Blood Spots on Filter Paper Using an Ultra-Microanalytical System  
*Applied Biochemistry and Biotechnology* 2018; 186: 1034 - 1046

**Martins JP., Forte GC., Simon MISD., Epifanio M., Pintos LA., Marostica PJC.**  
The role of neonatal screening in nutritional evolution in the first 12 months after diagnosis of cystic fibrosis  
*Revista Da Associação Médica Brasileira* 2018; 64: 1032 - 1037

**Mosconi P., Colombo C., Roberto A., Candiani G., Greco MT., Satolli R., Castellani C.**  
Deciding on cystic fibrosis carrier screening: three citizens' juries and an online survey  
*European Journal of Public Health* 2018; 28: 973 - 977

**Pecellin ID., Ruiz EP., Rios AIA., Pecellin CD., Macias RY., Hernandez LC., Luque IM., Aguilera PC., Valera MJM., Gallego MEQ.**  
Results of the Andalusian Cystic Fibrosis Neonatal Screening Program, 5 Years After Implementation  
*Archivos de Bronconeumología* 2018; 54: 551 - 558

**Zeevi DA., Zahdeh F., Kling Y., Rosen T., Renbaum P., Ron-El R., Eldar-Geva T., Holzer HEG., Levy-Lahad E., Altarescu G.**  
Noninvasive paternal exclusion testing for cystic fibrosis in the first five to eight weeks of gestation  
*Scientific Reports* 2018; 8: ArNo: 15941

## Therapy (Non Antimicrobial)

**Alves SP., Frank MD., Bueno D.**  
Medications used in pediatric cystic fibrosis population  
*Einstein-Sao Paulo* 2018; 16: 4:UNSP eAO4212

**Anderson SD., Daviskas E., Brannan JD., Chan HK.**  
Repurposing excipients as active inhalation agents: The mannitol story  
*Advanced Drug Delivery Reviews* 2018; 133: 45 - 56

**Bardin P., Sonnevile F., Corvol H., Tabary O.**  
Emerging microRNA Therapeutic Approaches for Cystic Fibrosis  
*Frontiers in Pharmacology* 2018; 9: ArNo: 1113

**Becker KA., Riethmuller J., Seitz AP., Gardner A., Boudreau R., Kamler M., Kleuser B., Schuchman E., Caldwell CC., Edwards MJ., Grassme H., Brodlie M., Gulbins E.**  
Sphingolipids as targets for inhalation treatment of cystic fibrosis  
*Advanced Drug Delivery Reviews* 2018; 133: 66 - 75

**Cho DY., Zhang SY., Lazrak A., Grayson JW., Garcia JAP., Skinner DF., Lim DJ., Mackey C., Banks C., Matalon S., Woodworth BA.**  
Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease  
*International Forum of Allergy & Rhinology* 2019; 9: 100 - 105

**Clancy JP.**  
Rapid therapeutic advances in CFTR modulator science  
*Pediatric Pulmonology* 2018; 53:

**Crawford KJ., Downey DG.**  
Therotyping in cystic fibrosis  
*Current Opinion in Pulmonary Medicine* 2018; 24: 612 - 617

**Davies JC., Moskowitz SM., Brown C., Horsley A., Mall MA., McKone EF., Plant BJ., Prais D., Ramsey BW., Taylor-Cousar JL., Tullis E., Uuer A., McKee CM., Robertson S., Shilling RA., Simard C., Van Goor F., Waltz D., Xuan F., Young**  
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles  
*New England Journal of Medicine* 2018; 379: 1599 - 1611

**Dentice R., Elkins M.**  
Timing of dornase alfa inhalation for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 11:CD007923

**Diab-Caceres L., Giron-Moreno RM., Pastor-Sanz MT., Quintana-Gallego E., Delgado-Pecellin I., Blanco-Aparicio M., Maiz L., Garcia-Clemente MM., Luna-Paredes C., Mondejar-Lopez P., Ruiz-de-Valbuena M., Fernandez O., Barrio M., Gonzalez M**  
Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience  
*Archivos de Bronconeumología* 2018; 54: 614 - 618

**Dobra R., Edmondson C., Hughes D., Martin I., Davies JC.**  
Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review  
*Pediatric Drugs* 2018; 20: 555 - 566

**Donaldson SH., Laube BL., Corcoran TE., Bhambhani P., Zeman K., Ceppe A., Zeitlin PL., Mogayzel PJ., Boyle M., Locke LW., Myerburg**  
MM., Pilewski JM., Flanagan B., Rowe SM., Bennett WD.  
Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR  
*JCI Insight* 2018; 3: 24:e122695

**Hamilton CM., Hung M., Chen G., Qureshi Z., Thompson JR., Sun BY., Bear CE., Young RN.**  
Synthesis and characterization of a photoaffinity labelling probe based on the structure of the cystic fibrosis drug ivacaftor  
*Tetrahedron* 2018; 74: 5528 - 5538

**Hammond JA., Connett GJ.**  
The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis  
*Paediatric Respiratory Reviews* 2018; 27: 16 - 17

**Jennings MT., Flume PA.**  
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies  
*Annals of the American Thoracic Society* 2018; 15: 897 - 902

**Keating D., Marigowda G., Burr L., Daines C., Mall MA., McKone EF., Ramsey BW., Rowe SM., Sass LA., Tullis E., McKee CM., Moskowitz SM., Robertson S., Savage J., Simard C., Van Goor F., Waltz D., Xuan FJ., Young T., et al**  
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles  
*New England Journal of Medicine* 2018; 379: 1612 - 1620



**Labonte ML.**

The Mist Tent: An Analysis of Therapeutic Change in the History of Cystic Fibrosis Care  
*Bulletin of the History of Medicine* 2018; 92: 634 - 663

**Maiuri L., Kroemer G.**

Autophagy delays progression of the two most frequent human monogenetic lethal diseases: cystic fibrosis and Wilson disease  
*Aging-us* 2018; 10: 3657 - 3661

**McElvaney OJ., Gunaratnam C., McElvaney OF., Bagwe I., Reeves EP., McElvaney NG.**

Emerging pharmacotherapies in cystic fibrosis  
*Expert Review of Respiratory Medicine* 2018; 12: 843 - 855

**Millar BC., Rendall JC., Downey DG., Moore JE.**

Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against *Pseudomonas aeruginosa*? Results of an in vitro study  
*Journal of Clinical Pharmacy and Therapeutics* 2018; 43: 836 - 843

**Mitchell RM., Jones AM., Barry PJ.**

CFTR modulator therapy in patients with cystic fibrosis and an organ transplant  
*Paediatric Respiratory Reviews* 2018; 27: 6 - 8

**Ooi CY., Syed SA., Rossi L., Garg M., Needham B., Avolio J., Young K., Surette MG., Gonska T.**

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation  
*Scientific Reports* 2018; 8: ArNo: 17834

**Phuan PW., Son JH., Tan JA., Li C., Musante I., Zlock L., Nielson DW., Finkbeiner WE., Kurth MJ., Galletta LJ., Haggie PM., Verkman AS.**

Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators  
*Journal of Cystic Fibrosis* 2018; 17: 595 - 606

**Pohl K., Nichols DP., Taylor-Cousar JL., Saavedra MT., Strand MJ., Nick JA., Bratcher PE.**

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation  
*PLoS One* 2018; 13: 12:e0209026

**Pollard BS., Pollard HB.**

Induced pluripotent stem cells for treating cystic fibrosis: State of the science  
*Pediatric Pulmonology* 2018; 53:

**Rodriguez-Miguel P., Lee N., Tucker MA., Csanyi G., McKie KT., Forseen C., Harris RA.**

Sildenafil improves vascular endothelial function in patients with cystic fibrosis  
*American Journal of Physiology-heart and Circulatory Physiology* 2018; 315: H1486 - H1494

**Sawicki GS., Fink AK., Schechter MS., Loeffler DR., Mayer-Hamblett N.**

Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States  
*Journal of Cystic Fibrosis* 2018; 17: 742 - 746

**Sharma D., Xing S., Hung YT., Caskey RN., Dowell ML., Touchette DR.**

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States  
*Orphanet Journal of Rare Diseases* 2018; 13: ArNo: 172

**Southern KW., Patel S., Sinha IP., Nevitt SJ.**

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 8:CD010966

**Stallings VA., Sainath N., Oberle M., Bertolaso C., Schall JI.**

Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations  
*Journal of Pediatrics* 2018; 201: 229 - +

**Trimble A., McKinzie C., Terrell M., Stringer E., Esther CR.**  
Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding  
*Journal of Cystic Fibrosis* 2018; 17: 779 - 782

**Trimble AT., Brown AW., Laube BL., Lechtzin N., Zeman KL., Wu JH., Ceppe A., Waltz D., Bennett WD., Donaldson SH.**  
Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis  
*Journal of Cystic Fibrosis* 2018; 17: 650 - 656

**Vadagam P., Kamal KM., Covvey JR., Giannetti V., Mukherjee K.**

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis  
*Journal of Managed Care & Specialty Pharmacy* 2018; 24: 987 - +

**Wang YT., Cai ZW., Gosling M., Sheppard DN.**

Potiation of the cystic fibrosis transmembrane conductance regulator Cl<sup>-</sup> channel by ivacaftor is temperature independent  
*American Journal of Physiology-lung Cellular and Molecular Physiology* 2018; 315: L846 - L857

**Wark P., McDonald VM.**

Nebulised hypertonic saline for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 9:CD001506

**Yang CN., Montgomery M.**

Dornase alfa for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2018; : 9:CD001127

**[Anonymous].**

Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis  
*Medical Letter On Drugs and Therapeutics* 2018; 60: 174 - 176

## Transplantation

**Ahmad O., Shafii AE., Mannino DM., Choate R., Baz MA.**

Impact of donor lung pathogenic bacteria on patient outcomes in the immediate posttransplant period  
*Transplant Infectious Disease* 2018; 20: 6:e12986

**Lenihan M., Mullane D., Buggy D., Flood G., Griffin M.**

Anesthesia for Lung Transplantation in Cystic Fibrosis: Retrospective Review from the Irish National Transplantation Centre  
*Journal of Cardiothoracic and Vascular Anesthesia* 2018; 32: 2372 - 2380

**Li SS., Tumin D., Krone KA., Boyer D., Kirkby SE., Mansour HM., Hayes D.**

Risks associated with lung transplantation in cystic fibrosis patients  
*Expert Review of Respiratory Medicine* 2018; 12: 893 - 904

**Morlacchi LC., Greer M., Tudorache I., Blasi F., Welte T., Haverich A., Mainz JG., Gottlieb J.**

The burden of sinus disease in cystic fibrosis lung transplant recipients  
*Transplant Infectious Disease* 2018; 20: 5:e12924

**Onyearugbulem C., Williams L., Zhu HR., Gazzaneo MC., Melicoff E., Das S., Coss-Bu J., Lam F., Mallory G., Munoz FM.**

Risk factors for infection after pediatric lung transplantation  
*Transplant Infectious Disease* 2018; 20: 6:e13000

**Savi D., Mordenti M., Bonci E., Troiani P., Giordani B., D'Alu V., Bertasi S., Cimino G., Rossi P., Poggi C., Palange P., Quattrucci S.**

Survival After Lung Transplant for Cystic Fibrosis in Italy: A Single Center Experience With 20 Years of Follow-up  
*Transplantation Proceedings* 2018; 50: 3732 - 3738

**Skogeland U., de Monestrol I., Godsken TE.**

Experiences of Individuals Awaiting Lung Transplantation  
*Respiratory Care* 2018; 63: 1535 - 1540

**Waseda R., Benazzo A., Hoetzenecker K., Jaksch P., Murakozy G., Gruber S., Roth G., Szepfalusi Z., Nachbaur E., Klepetko W.**

The influence of retransplantation on survival for pediatric lung transplant recipients  
*Journal of Thoracic and Cardiovascular Surgery* 2018; 156: 2025 - +

## **Urology**

**Young JG.**

Urinary tract stones in cystic fibrosis

*Paediatric Respiratory Reviews* 2018; 27: 21 - 23

